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SUMMARY 
 
Nasopharyngeal carcinoma (NPC) is one of the most common carcinoma found 
in the Southern Chinese and Asian population. It is closely associated with Epstein-Barr 
virus (EBV). Although it is a general concept from early studies that EBV infection 
resulting in NPC tumour formation is predominantly restricted to the latency stage, 
present studies have suggested that some EBV lytic genes may be expressed in NPC 
biopsies and contribute to the development of oncogenesis. 
By using reverse transcriptase polymerase chain reaction (RT-PCR) techniques, 
we have successfully constructed a profiling system which can detect EBV RNA 
expression and used this system to investigate the expression in NPC biopsies. Our 
results show that some EBV lytic genes are transcribed in NPC biopsies in addition to 
the latent genes that have been known to express. Among lytic genes, BHLF1 is found 
to be expressed in NPC for the first time in this study. This study is also the first 
comprehensive study of EBV gene expression in NPC.  
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1.1 EPSTEIN-BARR VIRUS (EBV) 
Epstein-Barr virus (EBV) is ubiquitous human herpesvirus, infecting about 95% 
of the adult population worldwide. Primary infection with EBV generally occurs in 
early childhood and is asymptomatic. EBV can coexist with most human host without 
causing diseases. However in some individuals this virus is the causative agent of 
infectious mononucleosis and associated with the development of variety of human 
cancers, including B-cell neoplasms such as Burkitt’s lymphoma, Hodgkin’s disease 
(HD), certain forms of T-cell lymphoma and some epithelial tumours such as 
nasopharyngeal carcinoma (NPC) (Rickinson & Kieff, 1996). 
 
1.1.1 Classification   
EBV is a gammaherpesvirus of the Lymphocryptovirus (LCV) genus. Herpesvirus 
family includes 3 subfamilies: the alphavirus subfamily includes Herpes Simplex virus I, 
II and Varicellazoster virus; betaherpesvirus include Cytomegalovirus and Human 
Herpesvirus 6 and 7; gammaherpesvirus include Human Herpesvirus 8 and EBV. 
The gammaherpesvirus subfamily includes gamma 1 (LCV) and gamma 2 or 
Rhadinovirus (RDV) genera. EBV is the only human LCV. Two subtypes of EBV are 
known to infect human: EBV type 1 and type 2. Type 1 is far more common in most 
infected populations. The two types differ in the genes that code for EBV nuclear 
protein (EBNA): EBNA-2, EBNA-3a, EBNA-3b, EBNA-3c and EBNA-LP (Kieff & 
Rickinson, 2001).  
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1.1.2 Virus structure 
EBV has a toroid-shaped protein core which is wrapped with double-stranded 
DNA, a nucleocapsids with 162 capsomeres, a protein tegument between the 
nucleocapsids and the envelope, and an outer envelope with external glycoprotein 
spikes (Rickinson & Kieff, 1996).  
 
1.1.3 Genome structure 
EBV genome is a 184-kbp long, double-stranded, linear DNA. It consists of 
tandemly reiterated 0.5 Kbp terminal direct repeats (TR) at the ends, tandemly 
reiterated 0.3 Kbp internal direct repeat (IR1), short and long unique sequence domains 
(US, UL). The two sequence domains are separated by IR1. When EBV infects a cell, 
the linear DNA genome becomes a circular episome with a characteristic number of 
terminal repeats and this is the common form of EBV genome in vivo. In some 
situations, the EBV genome can integrate into the host chromosome (Kieff & Rickinson, 
2001). 
Since the EBV genome was sequenced from the BamHI fragment library, EBV 
open reading frames (ORFs) frequently named based on their location in BamHI 
fragments which from A to Z, and a to e, in descending order of the fragment sizes (See 
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Fig. 1 The BamHI fragments on EBV genome. Diagram showing the location of 
BamHI fragments on the prototype B95-8 EBV genome. The origin of plasmid 
replication (oriP) and the terminal repeats (TR) are indicated in the diagram. 
 
 
1.1.4 EBV infection of cells in vitro 
EBV has a strong tropism for human B lymphocytes in vitro, and EBV entry into 
these cells is mediated by a viral envelope glycoprotein gp350/220 which is the most 
abundant envelope glycoprotein of EBV. It can bind to a B lymphocyte cell surface 
protein CD21 (CR2) which is a receptor for EBV and the C3d component of 
complement, and allow EBV to absorb to the cells. Though EBV can infect epithelial 
cells in vivo, it is not easy for EBV to infect and transform epithelial cells in vitro. 
Previous studies suggested that EBV glycoprotein gH and EBV-specific 
immunoglobulin A (IgA) may be associated with EBV infection in epithelial cells in 
vivo (Sixby et al., 1992; Molesworth et al., 2000).  
Infection of primary human B lymphocytes with EBV results in conversion and 
continuous proliferation into long term lymphoblastoid cell lines (LCLs). During 
growth transformation virus does not replicate and produce progeny virons but rather is 
replicated by host DNA polymerase as an extrachromosomal episome. This is called 
latent infection.  
OriP 
TR 
C W W W W Y  H  F  Q  U  P O M S L  E  Z R K  B    G   D  T X V  I    A 
TR 
TR 
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EBV-latent infected cells can be reactivated to get into lytic infection to produce 
viral progeny in vivo. Because there is no in vitro system naturally permissive for EBV 
lytic cycle, lytic EBV infection is usually studied by inducing latently infected cells to 
become permissive for lytic virus replication. Phorbol esters are reliable and broadly 
applicable inducers. Following induction, a variable proportion of cells become 
permissive for virus replication and undergoes cytopathic changes (Kieff & Rickinson, 
2001). 
 
1.1.4.1 Latent infection 
EBV latently infected cells express a limited number of viral genes known as 
latent genes. EBV latent genes include the viral nuclear antigen family (EBNA): 
EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-LP; latent membrane 
proteins (LMP): LMP1, LMP2A, LMP2B; two small nonpolyadenylated noncoding 
transcripts: EBER1 and EBER2 and a complex family of spliced, polyadenylated 
BamHI A rightward transcripts (BARTs). 
    
1.1.4.1.1 Latent gene function 
EBNA-LP 
      EBV Nuclear Antigen Leader Protein (EBNA-LP) is an initial gene product that 
is expressed together with EBNA-2 following EBV infection of B cells in vitro (Sample 
et al., 1986). EBNA-LP is considered important for EBV-induced B-cell 
immortalization based on the observation that EBNA-LP mutant viruses show severely 
impaired transforming activity (Mannick et al., 1991). The major function of EBNA-LP 
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is to stimulate EBNA-2-mediated transcriptional activation of viral and cellular genes 
such as LMP-1 and cyclin D2 (Nitsche et al., 1997; Sinclair et al., 1994). EBNA-LP 
also interacts with many cellular proteins such as pRb, p53, heat shock protein 70 
family (hsp72/hsc73), HS1-associated protein X1, bcl-2, HA95, protein kinase A 
(Szekely et al., 1993; Matsuda et al., 2003; Mannick et al., 1995; Han et al., 2001). 
These data suggest EBNA-LP may have multiple functions in B-cell transformation by 
modulating some components of the cellular machinery. 
 EBNA2 
      EBNA2 is a transactivator that controls several viral and cellular genes 
expression. It is believed to be a key protein for B-cell immortalization. The function 
the EBNA2 is recognized by a transformation-incompetent but replication-competent 
laboratory EBV strain P3HR-1, which deletes the gene coding for EBNA2 (Bornkamm 
et al., 1982). EBNA2 can activate other EBV latent gene expression by transactivating 
the Bam HI-C-promoter (Cp) which partially controls the genes expression of EBNAs, 
and the promoters of LMP1 and LMP2 (Sung et al., 1991; Abbot et al., 1990). EBNA2 
also shows the ability to regulate some cellular genes expression including the 
proto-oncogene c-myc as well as c-fgr, CD21, CD23 (a surface marker of activated 
B-cells), BLR2/EBI1 (the chemokine receptor) and represses transcription of the 
immunoglobulin heavy chain locus (Patel et al., 1990; Burgstahler et al., 1995; Cordier 
et al., 1993; Kaiser et al., 1999; Jochner et al., 1996). Based on these data, EBNA2 has 
a profound effect on host cells, and mediate immortalization of B lymphocyte.  
  Studies on how EBNA2 regulates other genes expression mechanism show that 
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EBNA2 can interact with a cellular DNA binding protein RBP-J. RBP-J is a 
transcriptional repressor protein, and can repress transcription by binding to a histone 
deacetylase complex (HDAC). EBNA2 relieve the repression of RBP-J by masking the 
transcriptional repression domain and replace the HDAC corepressor (Hsieh et al., 1995, 
1999). In this way, regulation of gene expression by EBNA2 is similar to Notch, a 
transmembrane receptor. Both of them modulate gene expression through interaction 
with RBP-J. EBNA2 could be regarded as a functional viral homologue of an activated 
Notch receptor (Jarriault et al., 1995).  
 EBNA3A, 3B, 3C 
Studies have shown that EBNA3A and EBNA3C are required for B-cell 
immortalization whereas EBNA3B is dispensable (Tomkinson et al., 1993). EBNA3s 
are transcriptional regulators and have the ability to inhibit transcriptional activation of 
EBNA2 responsive promoters. EBNA3s can bind with RBP-J and disrupt its binding to 
EBNA2, thus repressing the transactivation of EBNA2 (Robertson et al., 1996). It is 
proposed that ENBNA2 and EBNA3s work together to precisely regulate some viral 
and cellular gene expression by the antagonistic control of RBP-J activity. 
      Except counterbalance the action of EBNA2, EBNA3s may have the ability of 
transcription activation. EBNA3C can increase the production of LMP1 in the presence 
of EBNA2 (Zhao et al., 2000). Further researches on EBNA3C show it may disrupt 
multiple cell cycle checkpoints and induce nuclear division (Parker et al., 2000).  
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EBNA1  
EBNA1 is a sequence specific DNA binding phosphoprotein that is required for 
the replication and maintenance of the episomal EBV genome. This function is 
achieved through the binding of EBNA1 to oriP which contains multiple EBNA1 
binding sites. OriP is a cis-acting element in EBV genome. By associated with EBNA1, 
it enables the viral persistence of episomes in EBV infected-cells (Kieff & Rickinson, 
2001). EBNA1 is the only EBNA-associated with chromosomes during mitosis and is a 
key mediator of EBV DNA binding to chromosomes. EBNA1 also has some function in 
regulation of gene expression. For example, it can interact with two sites downstream of 
Qp to negatively regulate its own expression (Nonkwelo et al., 1996).   
 In addition, EBNA1 has a central role in maintaining latent EBV infection. 
EBNA1 has Gly-Ala repeats located in its N-terminal. The repeats may generate a 
cis-acting inhibitory signal that interferes with antigen processing and MHC class 
I-restricted presentation. It suggests that EBNA1 can enable EBV-infected cells to 
escape from CTL surveillance, and support EBV persistence in cells (Levitskaya et al., 
1995).   
LMP1 
The EBV latent membrane protein (LMP1) is a versatile protein and has profound 
effects on target cells. It is directly implicated in oncogenesis due to its ability to recruit 
several cellular proteins and stimulate different signal pathways.  
LMP1 consists of a short cytoplasmic N-terminus tail, six transmembrane 
domains and a long cytoplasmic C terminus (Coffin et al., 2001; Kaykas et al., 2002). 
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The C-terminal 200-aa sequence is important for function of LMP1. It can bind with 
several protein and participate in different signal pathway. For example: 1. The tumour 
necrosis factor receptor–associated factors (TRAFs) and TNFR-associated death 
domain protein (TRADD) can bind with the C-terminal domain, and mediate nuclear 
factor-κB (NFκB) activation. The activated NFκB can translocate from cytoplasm to the 
nucleus and regulate some target genes which are essential for cell proliferation and 
anti-apoptosis (Devergne et al., 1996). 2. Janus kinase 3 (JAK3) is also supposed to 
bind with C-terminal domain of LMP1, and activate signal transducer activator of 
transcription (STAT) to regulate transcription (Gires et al., 1999). 3. Recent studies 
show that PI3-K (phosphatidylinositol 3 kinase) /Akt (protein kinase B) pathway can be 
activated via the LMP1 C-terminal, and results in promoting cell survival and 
remodeling actin filament (Dawson et al., 2003).  
In summary, LMP1 uses several different signal pathways to disrupt normal 
gene expression and induce uncontrollable cellular growth, resulting in tumour 
formation.   
LMP2 
     LMP2 encodes 2 proteins: LMP2A and LMP2B. These two proteins are integral 
membrane proteins which share their 12 transmembrane domains and the short 
C-terminal tail. Their difference is in N-terminal domain: LMP2A carries an extra 
hydrophilic N-terminal domain of 119 amino acids compared to LMP2B (Longnecker 
et al., 1991). Both LMP 2A and 2B have been shown to be dispensable for lymphocyte 
transformation (Speck et al., 1999). LMP2A N-terminal domain includes some 
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phosphorylated tyrosine residues which may provide binding sites for the cellular 
protein containing Src homology 2 (SH2) (Longnecker et al., 1991). Several 
phosphotyrosine kinases (PTKs) bind to LMP2A via their SH2 domain and are then 
activated to regulate cellular growth. LMP2A expression in B cells results in the bypass 
of normal B-lymphocyte developmental checkpoints, allowing immunoglobulin 
negative cells to colonize peripheral lymphoid organs. It suggests that LMP2A may 
resemble B cell receptor (BCR), thus providing inappropriate developmental and 
survival signals to EBV infected B cell in latently infected human hosts (Caldwell et al., 
1998). 
Another possible function of LMP2A is that it can prevent the activation of lytic 
EBV by blocking BCR-mediated signal transduction (Miller et al., 1994). This function 
may be important in keeping EBV infected B-lymphocyte in their latent stages when 
these cells circulate in the peripheral blood and bone marrow. 
EBERs 
The EBV encoded, small, nonpolyadenylated, noncoding RNAs (EBERs) are by 
far the most abundant EBV RNAs in EBV-transformed cells. They localize to the cell 
nucleus and associate with cellular protein La and EAP (EBER-associated protein). 
Their function is not clear. Virus mutants with EBER gene deleted can transform 
lymphocyte. It suggests they may not be essential for transformation (Swaminathan et 
al., 1991).  
BARTs 
     Complementary-strand BamHI A rightward transcripts, known as BARTs, are 
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differentially spliced RNAs that are present in many types of EBV infections (Smith et 
al., 2001). Differential splicing of Bam A rightward transcripts yields a family of 
transcripts, which encompass an open reading frame BARF0. BARF0 is predicted to 
encode a 173-amino acid protein and NPC patients have shown to generate antibodies 
to the BARF0 polypeptide (Glligan et al., 1991). By using anti-BARF0 antiserum, a 
protein doublet of 30 and 35 kDa is identified in EBV-positive cell lines and 
EBV-positive tumour biopsies (Fries et al., 1997). These data indicate that proteins 
encoded by BARTs might be expressed.  
 
1.1.4.2 Lytic infection  
As discussed before, EBV-latent infected cells can be induced into lytic infection 
to produce viral progeny. After induction virus gene expression follows a temporal and 
sequential order, and all EBV lytic genes can be classified into 3 groups: 
immediate-early (IE) genes, early lytic genes and late genes. Immediate-early genes are 
expressed early after induction despite the presence of protein synthesis inhibitor. Early 
lytic genes are expressed before virus DNA replication, and their expression are 
dependent on some immediately-early genes expression. Late genes expressed 
temporally later, and their expression reduces markedly in the presence of viral DNA 
synthesis inhibitors.  
1.1.4.2.1 Immediate-Early (IE) genes 
       IE genes are essentially considered to cause the switch from latent infection to 
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lytic infection. However IE gene expression cannot be considered synonymous to full 
viral lytic replication (Rickinson & Kieff, 1996). IE genes include BZLF1, BRLF1, 
BRRF1 and the BI’LF4 (Segouffin et al., 2000; Marschall et al., 1991).  
 BZLF1, BRLF1  
      BZLF1 and BRLF1 encode two transcriptional activator proteins ZEBRA (Z, 
EB Replication Activator) and Rta (R transactivator) sequentially. Both proteins are 
essential for the switch from latency to lytic infection. They are expressed 
simultaneously within two hours of induction and consequently trigger a cascade of 
sequential expression of numerous early genes (Feederle et al., 2000).  
ZEBRA is a sequence-specific DNA-binding protein of 35 KD, and distantly 
related to c-fos which binds DNA via degenerate AP-1 and CREB-like binding sites 
(Farrell et al., 1989). Previous study shows that introduction of the BZLF1 gene of 
Epstein-Barr virus into latently-infected B cells leads to induction of the entire lytic 
cycle program of the virus (Takada et al., 1986). Rta is also shown to be able to disrupt 
latency in epithelial cells and in certain B cell lines (Zalani et al., 1996; Ragoczy et al., 
1998). Some studies suggest Rta can regulate gene expression via DNA binding 
dependent and independent mechanisms (Gutsch et al., 1994).  
BZLF1 is silent during latency, and its expression is controlled by the Zp 
promoter (Miller et al., 2002). ZEBRA activates target genes by binding to Z-responsive 
elements (ZREs) which are present in the promoters of some EBV genes, including the 
promoters of BZLF1 and BRLF1 (Kieff and Rickinson, 2001). BRLF1 expression is 
controlled by Rp promoter, and several cis elements involved in regulating Rp activity 
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including sites for binding cellular transcription factors NF1, Sp1, YY1, Zif and EBV 
ZEBRA. ZEBRA can activate Rta in all cell backgrounds that have been studied, and 
Rta can activate ZEBRA only in certain cell background (Zalani et al., 1996).  Recent 
research shows that Rp is only weakly responsive to the lytic cycle inducer TPA and 
ionomycin. It suggests ZEBRA protein expression precedes transcription of BRLF1 
(Pingfan et al., 2003).           
BZLF1 and BRLF1 can work together to regulate many EBV gene expression. 
For example, two key early promoter regulatory elements within DL and DR 
(duplication, left and right) are coordinately up-regulated by ZEBRA and Rta. DL and 
DR encode abundant early genes and include the origins for lytic viral DNA replication. 
Promoter activation has a strong positive effect on DNA synthesis (Kieff and Rickinson, 
2001).  
Besides a role in activating EBV early and late gene expression, ZEBRA can 
down-regulate the latency associated promoters CP and WP. Perhaps it facilitates the 
transition from latency to lytic cycle (Sinclair et al., 1992). In addition to its 
involvement in viral genes expression, ZEBRA may interfere with IFNγ signal pathway 
to abrogate the IFNγ induced MHC-II up-regulation and thereby contribute to the 
immune escape for the latently EBV infected B cells (Morrison et al., 2001).  
 
1.1.4.2.2 Early genes 
     EBV early genes are different from late genes by their persistent transcription in 
the presence of inhibitors of viral DNA synthesis. At least 30 EBV genes belong to early 
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genes based on this criterion. (Kieff and Rickinson, 2001)   
BS-MLF1 
The EBV nuclear protein BS-MLF1 (SM) is expressed early after entry of EBV 
into the lytic cycle. It is a posttranscriptional regulator of viral gene expression and 
essential for virion production (Gruffat et al., 2002). SM protein can activate intronless 
genes expression and inhibit expression of intron-containing genes (Ruvolo et al., 1998). 
In contrast to the majority of cellular genes, many EBV genes expressed during lytic 
cycle are intronless, and SM may therefore be important in enhancing expression of 
other lytic EBV genes. In addition, SM shows gene specificity, preferentially activating 
expression of some but not all intronless genes (Ruvolo et al., 2001). Except regulation 
of viral gene expression, SM protein can increase expression of some cell genes, such 
as some interferon-stimulated genes and STAT1 (Ruvolo et al., 2003).  
BHRF1 
BHRF1 protein is expressed primarily during lytic infection and is dispensable 
for lymphocyte transformation (Lee et al., 1992). This protein shows partial sequence 
homology to the human apoptosis inhibitor bcl-2. Further research shows BHRF1 
resembles bcl-2 both in its subcellular localization and in its capacity to enhance B-cell 
survival (Henderson et al., 1993). It suggests BHRF1 may enhance cell survival through 
the inhibition of apoptosis (Oudejans et al., 1995).      
BARF1 
The BARF1 gene encodes a 31-kDa early protein which was shown to be able to 
induce malignant transformation in BALB/c3T3 cells and in the human B-cell line 
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Louckes. Injection of BARF1-expressing BALB/c3T3 cells into newborn rats resulted in 
the induction of aggressive tumours, while injection of BARF1-expressing Louckes 
human EBV-negative B cells into the same mouse induced the formation of a small 
tumour that regressed after 3 weeks (Wei et al., 1989). This gene was found to be 
expressed in NPC biopsies, and was shown to have the ability to immortalize primary 
monkey epithelial cells (Decaussin et al., 2000; Wei et al., 1997). It suggests that this 
gene maybe has a role in the development of NPC. 
BARF1 can activate anti-apoptotic Bcl-2 expression through its N-terminal 
region. The cooperation of BARF1 with Bcl-2 maybe contributes to the induction of 
transformation (Sheng et al., 2001). Some studies also show that BARF1 protein has 
some homology to the intracellular adhesion molecule 1 and the human 
colony-stimulating factor-1 receptor. Therefore BARF1 may be involved in immune 
suppression by being an antagonist to colony-stimulating factor 1 receptor or by 
occupying intracellular adhesion molecule 1 receptor on T lymphocytes (Strockbine et 
al., 1998).  
    
1.1.4.2.3 Late genes 
      Most late genes that can be identified directly or based on their homology with 
other herpesvirus genes encode structural proteins. For example, late gene BcLF1 
encodes viral capsid antigen (VCA), BFRF3 encodes the small capsid protein VCA-p18, 
BdRF1 encode the scaffold protein VCA-p40 (van Grunsven et al., 1993; Baer et al., 
1984). The viral glycoprotein genes that have been identified are all late genes, 
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including BLLF1 (gp350/220), BALF4 (gp110), BILF1 (gp64), BBRF3 (gp84/113), 
BXLF2 (gp85), etc (Kieff and Rickinson, 2001).  
 BCRF1 
      BCRF1 protein shows amino acid sequence homology to human interleukin 10 
(hIL-10) (Vieira et al., 1991). hIL-10 has the ability to inhibit the activation and effector 
function of T cells, monocytes and macrophages, and is a potent growth and 
differentiation factor for B lymphocytes (Rousset et al., 1992). Studies suggest BCRF1 
is functionally homologous to hIL-10. They share the ability to modulate local immune 
response (Moore et al., 1991). Therefore BCRF1 may enhance the survival of 
EBV-infected cells by suppression of the host immune system. 
 
1.1.5 EBV infection in vivo  
1.1.5.1 Primary infection  
EBV is transmitted from person to person through saliva which contains 
infectious virus and/or productively infected cells (Yao et al., 1985). Primary infection 
may begin at oropharynx. EBV may infect oropharyngeal epithelium first and replicate 
in these infected cells, and then release virus to infect the B lymphocyte which is close 
to the epithelial cells (Greenspan et al., 1985). However, this sequence of infectivity is 
under debate. Some researchers suggest that B cells may be the main target of primary 
infection, and epithelial cells infection is occurred as the consequence of local 
reactivation of the virus from EBV-carrying B lymphocytes. This hypothesis is based on 
the observation: 1. EBV was found in B-lymphocytes but not in epithelial cells in the 
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tonsil form IM patients (Niedobitek et al., 1997). 2. X-linked agammaglobulinemoia 
patients who have no matured B-lymphocytes are free of EBV infection (Faulkner et al., 
1999).  
Until now, it is general concept that EBV primary infection occurs at mucosal 
surfaces, but whether epithelial-cell infection is the first step of virus infection remains 
unresolved. Most people undergo asymptomatic primary infection during early 
childhood. Delayed primary infection can occurs in adolescence and can cause 
infectious mononucleosis (IM). In either case, primary infection is followed by life long, 
mostly asymptomatic, persistent infection (Niedobitek et al., 2000). 
 
1.1.5.2 Different transcription programs used by EBV in vivo  
      After primary infection, EBV can persist in human B cells, but the viral gene 
expression pattern in B cells in vivo is different from in vitro experiment. In general, the 
expression patterns can be defined in 5 stages, which are described in the following. 
1. In healthy carriers, EBV mainly stays in memory B cells which are in a resting 
stage where no viral proteins are expressed (Hochberg et al., 2004). This gene 
expression pattern is called latency (resting) program. 
2. In dividing memory B cells, only EBNA1 protein is expressed. This gene 
expression pattern is called latency (dividing) program. 
3. B cells that express all EBV latent genes are found only in the lymph nodes and 
this gene expression pattern is known as the growth program (Joseph et al., 2000). 
This is equivalent to the latency program of infected B-lymphocyte in vitro. 
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4. EBV infected B cells in the germinal center may express EBNA1, LMP1 and 
LMP2A protein and this is called default program (MacLennan et al., 1988). 
5. EBV lytic infection which can be found in some plasma cells in the Waldeyer’s 
ring is known as lytic program. 
Different programs may have different function in the process of establishment of 
EBV life-long infection in humans (Thorley & Gross, 2004). These possible functions 
are discussed in next part. The different transcription programs of EBV in vivo and its 
possible functions are summarized in Table 1. 
 
     Table 1. Transcription programs used by EBV to establish long life infection 




Genes expressed Possible functions 
Naive cell  Growth EBNA1, EBNA2, 
EBNA3, LMP1 and 
LMP2 
Activates B cells  
Germinal-center 
cell  
Default  EBNA1, LMP1 and 
LMP2A 
Differentiates 
activated B cells into 












EBNA1 Allows viral DNA in 
latency program cell 
to divide 
Plasma cell Lytic All lytic genes Replicates virus in 
plasma cell 
 
1.1.5.3 EBV lifecycle in vivo   
During initial infection, EBV infects the naive B cells in or below the mucosal 
epithelium, expressing viral genes in what we previously known as the growth program. 
Similar to in vitro experiments, the infected cells are transformed into proliferating B 
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lymphoblasts. However, the EBV infected B lymphoblasts cannot exist in vivo for long 
periods of time due to the strong cytotoxic T cell (CTL) response against EBV infected 
B lymphoblasts which arises soon after primary infection in normal people (Khanna et 
al., 1995; Joseph et al., 2000). 
In order to have long term persistence in the human host, EBV chooses resting 
memory B-cells as its host cell in vivo. One hypothesis about how EBV gets into 
memory B-cell is that EBV may cause infected B lymphoblasts to differentiate into 
resting memory B-cells in the germinal center soon after infection. This pathway 
mimics the way that antigen-activated B cell blast differentiates into a long living 
memory B cell after primary infection. In the germinal center, the EBV infected B-cell 
transiently expresses EBV latent genes EBNA1, LMP1 and LMP2A during division 
(default program). As discussed before, LMP2A could replace B cell receptor (BCR) 
function in B cell development to send rescue signals to infected cells, resulting in 
immunoglobulin-negative cells to colonize peripheral lymphoid organs (Caldwell et al., 
1998). LMP 1 can promote B-cell survival and growth through the c-Jun N-terminal 
kinase (JNK) signal cascade. It is suggested that LMP1 mimic the B-cell activation 
processes which are physiologically triggered by CD40-CD40 ligand signals to sustain 
B-cell proliferation (Kilger et al., 1998). In summary, with expression of the default 
program, EBV may cause a B blast cell to differentiate into a memory B cell and get 
into the lymph circulation. 
By staying in resting memory B cells at frequency of 1 in 1×105 to 1×106 cells, 
EBV can exist in host for long time without eliminated by immune system (Wagner et 
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al., 1992). In memory B cells, no viral protein is expressed (latency program). Only 
when the infected memory B cells divide, EBV EBNA1 is expressed to allow viral 
DNA to replicate (Hochberg et al., 2004). 
Some infected memory B cells can get back to the lymphoepithelial tissue of 
oropharynx and be reactivated into the lytic cycle to produce viral progeny. Recent 
studies have shown that the infected B cells express all lytic genes (lytic program) to 
produce infectious virus when memory B cells differentiate into plasma cells in 
Waldeyer’s ring (Thorley & Gross, 2004). The released virions can not only get into 
saliva to infect other people, but also can infect B lymphocytes in the host. Until now, 
we know little about the signals that disrupt the viral latency state and initiate the lytic 
cycle in vivo. Some studies have shown that the signal for B-cell terminal differentiation 
may possibly be the signal for EBV reactivation (Crawford et al., 1986; Mellinghoff et 
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Fig. 2 EBV life cycle in vivo. Diagram describing the EBV life cycle and different 
transcription programs used by EBV in different stage of its life (Thorley & Gross, 
2004).   
 
1.1.6 EBV associated malignancies 
      EBV has been implicated in the development of a wide range of malignancies, 
including Burkitt’s lymphoma, Hodgkin’s disease, non-Hodgkin’s lymphoma, 
nasopharyngeal carcinoma, gastric cancer, breast cancer, posttransplant 
lymphoproliferative disorders (PTLDs), AIDS-associated lymphomas and 
leiomyosarcomas in immunosuppressed individuals (Thompson et al., 2004). Based on 
different latent gene expression in different diseases, EBV latent infection has been 
classified into 3 types. Gene expression patterns in different latency types are listed in 
Table 2 (Kieff & Rickinson, 2001). Latency type I, II and III correspond to latency 















Periphery Tonsil Saliva 
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Latency type      I       II Ш 
EBNA1       +       +       + 
EBNA-2,LP,3A-C                         + 
LMP1, LMP2                +       + 
EBERs      +       +       + 
BARTs      +       +       + 
Example BL     HD, NPC          ARLs 
 
Table 2. Gene expression in different types of EBV latent infection  
 BL: Burkitt’s lymphoma; HD: Hodgkin’s disease; NPC: Nasopharyngeal carcinoma; 
 ARLs: AIDS-related lymphomas. 
 
1.1.6.1 Burkitt’s Lymphoma (BL)  
BL is a B-cell lymphoma that was originally described in equatorial Africa where 
it accounts for approximately half of all childhood cancers (Burkitt et al., 1961). BL can 
be separated into two types: endemic and nonendemic BL. Endemic BL occurs 
primarily in equatorial Africa and New Guinea, and EBV is present in approximately 
95% of cases (Magrath et al., 1992). Nonendemic BL is found in the Europe and the 
USA. Only 15%-30% of nonendemic BL cases are associated with EBV in the USA 
(Subar et al., 1988).  
In vitro experiments, Akata BL cell line subcultures that lost EBV cannot induce 
tumours in mice and lose malignant phenotypes, and reinfection of Akata cells with 
EBV can restore the malignant phenotypes (Shimizu et al., 1994; Komano et al., 1998). 
These data supports the association between EBV and BL. In endemic BL biopsy, 
expression of EBV latent genes can be detected, and the expression pattern belongs to 
latency type I, only EBNA1, BARTs and EBER are expressed (Rowe et al., 1986).  
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1.1.6.2 Hodgkin’s Disease (HD) 
Hodgkin’s Disease is characterized by mononuclear Hodgkin cells and their 
multinucleated variant the Reed-Sternberg cells, together abbreviated as H-RS cells. 
These cells are now postulated to be of B-cell lineage (Lukes et al., 1966; Marafioti et al., 
1997). Several evidences support the linkage between EBV and HD. First, the 
individuals with a history of infectious mononucleosis (IM) have 4 fold increased risk of 
developing HD (Munoz et al., 1978.) Second, a retrospective analysis of serum sample 
showed increased antibody titers to EBV viral capsid antigen in HD patients (Mueller et 
al., 1989). Finally, the key finding is detection of EBV genomes and gene products in 
H-RS cells (Herbst et al., 1993). EBV latent genes EBNA-1, LMP1, LMP-2A, 2B, 
BARTs and EBERs are expressed in H-RS cells. This gene expression pattern belongs to 
latency type II. (Pallesen et al., 1991).        
 
1.1.6.3 Non-Hodgkin’s Lymphoma in Immunocompetent Individuals   
Except infecting B-cells, EBV can infect other cells and cause diseases. Several 
types of non-B-cells, non-Hodgkin’s lymphoma are associated with EBV, such as nasal 
T/ natural killer cell lymphoma and angioimmunoblastic lymphadenopathy (Jones et al., 
1988; Weiss et al., 1992). Nasal T/ natural killer non-Hodgkin’s lymphoma is a specific 
extranodal T-cell lymphoma which occurs in the nasal cavity. The consistent association 
between EBV with this lymphoma was first found in Japanese, and confirmed in 
Chinese and Caucasian patients. Based on previous study, expression of EBV latent 
genes in this lymphoma belongs to latency type II (Minarovits et al., 1994).  
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1.1.6.4 NPC 
      NPC is an epithelial carcinoma of nasopharynx. It is closely associated with the 
EBV infection. The association between EBV and NPC will be discussed in detail later.   
  
1.1.6.5 Posttransplant lymphoproliferative disorders (PTLDs)  
      PTLDs refer to a collection of clinically and pathologically diverse tumours, 
predominantly of B-lymphocyte origin, associated with therapeutic immunosuppression 
after organ transplantation. PTLDs arise in up to 10% of all transplant recipients and 
nearly all forms of disorders are associated with EBV (Nalesnik, 2002; Penn, 1994). In 
healthy individuals, EBV can establish lifelong asymptomatic latency in B-lymphocytes 
that is effectively controlled by EBV-specific cytotoxic T-lymphocytes (CTLs). 
Immunocompromised transplant recipients exhibit a profound deficit in cell-mediated 
immunity that leads to the disruption of the balance between EBV infection and 
EBV-specific CTLs. This change can cause uncontrolled EBV-driven B cell 
proliferation, and results in tumour formation and the onset of PTLDs (Knowles, 1998). 
By using RT-PCR and western blot method, a latency type Ⅲ-like EBV gene expression 
pattern can be found in early PTLDs (Young et al., 1989).  
     
1.1.6.6 AIDS-related lymphomas (ARLs) 
ARLs are a heterogeneous group of diseases which arise in the HIV-associated 
immunosuppression patients. These lymphomas are mostly B-cell origin and contain the 
patients’ intrinsic EBV (Knowles, 1999). Both type I and type II EBV strains are 
                                                                   Introduction                  
                                                      - 25 - 
detectable. This shows two types EBV can co-infect the host (Boyle et al., 1991). 
According to the EBV association and EBV gene expression patterns, ARLs can be 
separated into 2 types. One type is diffuse large B-cell lymphoma. This type is closely 
associated with EBV, and EBV gene expression pattern belongs to latency type III. 
Another type is AIDS-related BL. Only 30-40% cases of this type lymphoma are 
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1.2 NASOPHARYNGEAL CARCINOMA (NPC)  
Nasopharyngeal carcinoma (NPC) is a malignancy of the stratified squamous 
epithelium of nasopharynx. NPC is rare in most countries, but it has a high incidence 
South-East Asia. NPC is distinguished from other cancers of the head and neck by its 
histopathology, epidemiology, clinical characteristic and treatment (Muir et al., 1992). 
 
1.2.1 Histological classification  
Based on the classification of World Health Organization (WHO), NPC is 
classified into 3 histological types:  
• Type I: keratinising squamous cell carcinoma (SCC) 
• Type II: non-keratinising carcinoma 
• Type III: the undifferentiated carcinoma. 
Type III is the most common NPC type in people. According to some report, type 
II and III can be considered as undifferentiated carcinoma of the nasopharyngeal type 
(UCNT). Generally UCNT have a higher local control rate than SCC after treatment of 
radiotherapy (Reddy et al., 1995; Marks et al., 1998). 
 
1.2.2 Anatomy 
Nasopharynx can be defined as that portion of the pharynx which lies behind the 
nasal fossae and extends inferiorly as far as the level of the soft plate. Nasopharyngeal 
carcinoma usually originates in the fossa of Rosenmuller (lateral nasopharyngeal 
recess). It can then extend within or out of the nasopharynx to the other lateral wall 
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and/or posterosuperiorally to the base of the skull or the palate, nasal cavity or 
oropharynx. Many of the skull base foramens that carry important neural and vascular 
structures are located immediately adjacent to the nasopharynx. The nasopharynx is 
lined by mucosa that is covered with pseudostratified columnar epithelium and stratified 
squamous epithelium, and the mucosa is frequently infiltrated by lymphoid tissue. It is 
from this epithelium that nasopharyngeal carcinoma arises (Alan et al., 1999). 
 
1.2.3 Epidemiology 
Nasopharyngeal carcinoma incidence rate is less than 1 per 100,000 in most 
countries. But in southern china, especially in Cantonese region around Guangdong and 
Hong Kong, the NPC incidence rate is much higher. It is about 30-80 /100,000 people 
per year (Muir et al., 1992).  
NPC can occur in any age. In Asia the peak incidence is in the people aged 
between 50-60. Men are twice as likely to develop nasopharyngeal carcinoma as 
women (Spano et al., 2003).   
 
1.2.4 Clinical symptoms 
The early symptoms of NPC patients are minimal, and always ignored by patients 
and doctors. Until the carcinoma reach relatively advanced stage, the symptoms become 
clearly. The most common presenting symptom is cervical lymphadenopathy, followed 
by nasal and aural symptoms. Neurological complaints are less common and always 
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happen late. Only small part of patients presents distant metastases (Skinner et al., 
1991).  
 
1.2.5 Etiology   
NPC often occurs in specific race and area. This suggests that genetic and 
environmental factors may contribute to the oncogenesis of NPC. Until now, many 
studies reveal that genetic factor, EBV and environmental factor are associated with 
NPC.  
 
1.2.5.1 Genetic factor 
Cytogenetic studies had been done to investigate the chromosomal aberrations in 
the NPC cancer cells. Chromosome abnormalities of 1, 3p, 3q, 5q, 9p, 11q, 12, 13q, 14q, 
X and breakpoints in 1p11-31, 3p12-21, 3q25, 5q31, 11q13, 12q13, X 25 were observed. 
The deletion of short arm of chromosome 3 is the most common karyotypic defect in 
NPC (Lo et al., 1997).  
Through comparative hybridization (CGH) analysis, chromosomal gains and 
losses in primary NPC were checked. Chromosomal gain in 1q, 3q, 8, 12, 19 and loss in 
1p, 3p, 9p, 9q, 11q, 13q, 14q, 16q were found. The most frequent chromosomal regions 
showing gain and loss are 12 and 3p respectively (Hui et al., 1999). 
 
1.2.5.1.1 Inactivation of tumour suppressor genes  
Studies on these abnormal chromosomes suggest that inactivation of some 
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tumour suppressor genes and alteration of some oncogenes may play an important role 
in development of NPC. RASSF1A at chromosome 3p21.3, fragile histidine triad 
protein (FHIT) gene at chromosome 3p14.2, p16/INK4A at chromosome 9p, tumour 
suppressor in lung cancer 1 (TSLC1) at 11q23 and endothelin receptor β (EDNRB) at 
chromosome 13q22 are proposed to be the tumour suppressor genes involved. Their 
expression was down-regulated in NPC, especially p16. Lack of p16 protein is very 
common in NPC primary tumours (Chow et al., 2004; Deng et al., 2001; Lo et al., 1995; 
Hui et al.. 2003; Gulley et al., 1998; Lo et al., 2002). 
One possible way to inactive tumour suppressor genes is to hypermethylate the 
promoters of these genes. Studies showing that widespread aberrant methylation exist in 
NPC cells. Compared with some EBV negative neck and head cancers, the frequency of 
aberrant methylation is much higher in EBV associated NPC, which suggests the 
unusually close relationship of aberrant methylation and EBV infection (Kwong et al., 
2002). One scenario is that some EBV genes may cause methylation of some promoters 
of cellular genes, including the promoters of tumour suppressor genes, and results in 
down-regulation of the expression of these tumour suppressor genes. 
 
1.2.5.1.2 Oncogene activation 
Until now, our knowledge about oncogene alterations in NPC is still lacking. 
Some researches show that oncogenes bcl2, cyclin D1, c-myc, ras, PIK3CA and p63 are 
activated in primary tumours and may involve in the development of NPC (Lu et al., 
1993; Lai et al., 2002; Porter et al., 1994; Hui et al., 2002; Crook et al., 2000). Aberrant 
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activation of these oncogens may be caused by some cellular or viral genes.   
 
1.2.5.1.3 HLA association 
The human leukocyte antigen (HLA) was first demonstrated to be associated with 
NPC in Singapore Chinese. HLA-A2, B46 (originally termed BSin2) and A33, B58 
haplotype were found to be associated with high risk of NPC. On the contrary, people 
with HLA A11 and B13 seem not likely to develop NPC. One hypothesis about the role 
of HLA in NPC is that some particular HLA antigen cannot cause effective host 
immune response to EBV infection, and make the EBV persist in nasopharyngeal 
epithelial cells (Chan et al., 1981).  
      Further studies suggest that a gene closely linked to the HLA loci on short arm 
of chromosome 6 may confer greatly increased risk of NPC (Lu et al., 1990). 
Subsequent research showed that microsatellite locus D6S211 (allele 4) close to HLA-A   
region on chromosome 6 was associate with increased risk of NPC (Lu et al., 2003).  
      
1.2.5.2 Environmental factor 
Epidemiological data of NPC patients suggest that some environmental factors 
may contribute to the development of this carcinoma. Cantonese-style salted fish was 
suspected to be an important etiological factor for NPC. Case-control studies reveal the 
positive relationship between salted fish and NPC, and show higher risk of NPC is 
associated with earlier age exposed to salted fish (Yu et al., 1986; Ning et al., 1990). 
Animal model experiments strength the hypothesis. Rats fed with Chinese salted fish 
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can develop malignant nasal cavity tumours (Yu et al., 1989). 
Some preserved foods are also considered as nasopharyngeal carcinogens. These 
foods include salted and pickled leafy/stem vegetables and roots, salted and fermented 
eggs, fermented beans and bean pastes, and various seafood pastes. Carcinogenic 
nitrosamines / precursors and genotoxic and EBV-activating substances were detected 
in these foods (Yu et al., 1988; Poirier et al., 1989; Shao et al., 1988). Studies on 
low-risk population (white and black residents in the United States) show the increased 
risk of NPC is significantly associated with intake of the preserved food (Farrow et al., 
1998). 
Further research on cytochrome P450 2E1 (CYP2E1), an enzyme that can 
catalyzes the metabolic process of nitrosamines, show different CYP2E1 genotypes 
exhibit different risk of development of NPC. c2 / c2 genotype experienced 2.6-fold risk 
of NPC compared to the wild-type allele. This research strengthens the hypothesis that 
nitrosamine-containing preserved food is one of the causative agents for NPC 
(Hildesheim et al., 1997). 
Other possible environmental factors associated with NPC include some Chinese 
herbs, formaldehyde, tobacco and fewer intakes of fresh fruit and vegetables (Zeng et 
al., 1994; Blair et al., 1990; Yu et al., 1988). 
       
1.2.5.3 EBV infection: 
EBV was first suspected to be associated with NPC based on the observation that 
the sera from NPC patients contain antibodies against EBV-infected Burkitt’s 
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lymphoma cells (Old et al., 1966). By in-situ hybridization, researchers proved that the 
EBV DNA exists in the nuclei of epithelial cells of NPC patients, and the full length 
EBV genome is contained in all malignant epithelial cells but not in most infiltrating 
lymphocytes (zur Hausen et al., 1970). EBV-encoded small nuclear RNAs (EBERS) is 
usually present in high copy numbers in the malignant epithelial cells. It suggests viral 
transcription exist in those cells (Wu et al., 1991). Conversely, EBV is always negative 
in untransformed squamous epithelia from the nasopharyngeal mucosa (Lin et al., 1997). 
In addition, elevated titers of IgG and IgA against EBV viral antigens exist in NPC 
patients, especially high titers of IgA antibodies against EBV EA and VCA complex 
(Henle et al., 1970). All these data support the association between EBV and NPC. 
Serological studies show that the association between EBV and NPC type Ⅲ and 
type Ⅱare constant regardless of the patient’s geographical origin (Krueger et al., 1981), 
but the association between EBV and NPC typeⅠ is still controversial.  
               
1.2.5.3.1 EBV latent gene expression in NPC 
By studying NPC specimens, transcription of EBV EBNA-1, LMP-1, LMP-2, 
EBERs and BARTs are identified (Wu et al., 1991; Brooks et al., 1992; Sadler et al., 
1995). This gene expression pattern is characteristic of many EBV-associated tumours 
and is termed EBV latency type Ⅱ. At protein level, EBNA1 has been identified in 
most NPC biopsies, and LMP1 has been detected in about 50% of tumours (Young et al., 
1988). LMP 2 protein has not been detected in NPC samples, but serological analyses 
revealed that NPC patients have elevated titers antibody against this protein. It suggests 
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this protein may be expressed in NPC tumour (Frech et al., 1993).  
EBNA1 are stably expressed in all latently EBV-infected cells. Some data shows 
that expression of EBNA1 in an EBV-negative NPC cell line, which was then 
inoculated into both nude and severe combined immunodeficiency mice, can increase 
the tumourigenicity and metastatic capability of the cells. These data suggest that 
EBNA 1 may contribute to the development of NPC (Sheu et al., 1996).  
Unlike EBNA1, LMP1 is not consistently expressed in NPC biopsies. Though 
just about 50% NPC biopsies can detect LMP1 expression, serological study showed 
high titers of anti-LMP1 antibodies existed in more than 70% NPC patients, and high 
levels of serum anti-LMP1 correlated with more advanced stage of this carcinoma (Xu 
et al., 2000). Interestingly, by studying the preinvasive nasopharyngeal lesion related to 
NPC, including dysplasia and carcinoma in situ, LMP1 was found to be expressed in 
most cases. It suggests LMP1 may play a pathogenic role in the early stages of NPC 
development (Pathmanathan et al., 1995). As described in section 1.1.4.1.1, LMP1 has a 
profound effect on the EBV-infected cells. It is critical for the immortalization of 
primary B lymphocytes, and can induce proliferation in normal epithelial cells in vivo. 
It can make the transgenic mice highly sensitive to chemical carcinogens and develop 
significantly more small papillomas at a faster rate (Kaye et al., 1993; Curran et al., 
2001). Taken together, LMP1 may contribute to the development of NPC at early stage. 
Until now, the exactly function of LMP1 in tumourigenesis of NPC is far from clear. 
      Although LMP2 expression in NPC biopsies still needs to be confirmed, high 
titers of antibodies to LMP2 in most NPC patients suggests this protein may be 
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expressed during some stages of NPC. Available data about the function of LMP2 in 
NPC is limited. It seems that LMP2 has a different function in epithelial cells from that 
in lymphocytes. It may be involved in cell adhesion-initiated signaling pathways in 
epithelial cells (Scholle et al., 1999).  
 
1.2.5.3.2 Lytic genes expression in NPC  
Until now most research about the function of EBV in NPC is focused on the 
EBV latent genes; information about the possible involvement of lytic genes in NPC is 
limited. Though no viral particles are detected in tumour tissue in situ, more and more 
data suggest that some lytic genes are expressed in NPC biopsies.  
     The transcript of BRLF1, an important transcription activator, is detected in NPC 
biopsies. The IgG antibodies directed against BRLF1 were also detected in about 80% 
NPC plasma samples, but seldom in health carriers. This result indicates that the EBV 
immediate early lytic gene BRLF1 may be expressed in NPC (Feng et al., 2000). 
Previous study show BRLF1 can disrupt the viral latency in epithelial cells by itself 
through an epithelial specific mechanism (Zalani et al., 1996). Therefore, if BRLF1 is 
expressed in NPC tumour cells, it is possible that some other EBV lytic genes may be 
expressed in NPC. As for BZLF1, another important transcription activator, anti-BZLF1 
antibodies were present in sera of most NPC patients, and transcripts of BZLF1were 
also found in some NPC tumour biopsies (Cochet et al., 1993). The importance of 
BZLF1 expression in NPC is under debate.  
Early EBV gene BARF1 has been shown to be transcribed and translated in more 
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than 80% NPC biopsies, and antibodies against BARF1 were found in sera of NPC 
patients. Together with BARF1 has the ability to transform primary monkey epithelial 
cells. It seems likely BARF1 protein is expressed in NPC and may play a role in NPC 
development (Tanner et al., 1997; Wei et al., 1997).     
EBV lytic gene BGLF5 encodes EBV DNase. This protein was found to be 
expressed in both fresh biopsies and transplanted tumour lines (Sbih et al., 1996), and 
NPC patients frequently have increased serum level of antibodies directly against 
EBV-DNase (Chen et al., 1985). These foundlings suggest EBV lytic gene BGLF5 may 
be expressed in NPC. Other proteins encoded by EBV lytic genes, including early 
antigen diffuse components (EA-D) and restricted components (EA-R), probably are 
expressed in NPC biopsies, but studies on these proteins yield conflicting results (Luka 
et al., 1988).   
       In summary, the limited available data about EBV lytic gene expression in 
NPC biopsies raise the possibility that some lytic genes may be expressed in NPC and 
may contribute to the development of NPC.   
    
1.2.6 Diagnosis of NPC 
Clinical symptoms, radiological, serological and pathological data could be used 
to diagnose NPC. Here we just concentrate on the serological diagnosis. 
 
1.2.6.1 Serological diagnosis 
    NPC patients are very sensitive to radiotherapy at early stage, and have high 5 
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year survival rate which is about 70-80%, but in the patients with advanced stage the 5 
year survival rate drops to 20%-40%. Therefore diagnosing NPC at early stage is 
important for improving treatment (Vokes et al., 1997).  
The presence of EBV in epithelial and in B lymphocyte cells in NPC patients 
causes a humoral immune response to EBV antigens, including producing antibodies 
against some EBV antigens. Therefore, testing antibodies against EBV antigens become 
a useful and worldwide method for early diagnosing NPC (Zong et al., 1992). The 
typical anti-EBV serological profile of NPC patients consists of an increase in both IgG 
and IgA antibodies against the Viral Capsid Antigen (VCA) and Early antigen (EA). 
Other antibodies that have the potential to be used for diagnosis include anti-EBNA, 
anti-DNase, anti-TK, anti-DNA polymerase, anti-BRLF1 and anti-BZLF1 (Littler et al., 
1991; Liu et al., 1997; Joab et al., 1991).  
 
1.2.6.1.1 EBV EA and VCA antibodies  
Compared with other head and neck neoplasms, NPC patients have high IgG and 
IgA antibodies against EBV EA, VCA and MA complex (Henle et al., 1970). Among 
these antibodies, EBV specific IgA-EA and IgA-VCA are the most valuable diagnostic 
markers for NPC (Mazeron et al., 1996). The clinical use of these antibodies as markers 
for detecting NPC in high risk groups was confirmed by large population trials. 
Immunofluorescence assay (IFA) is now used to detect IgA-EA and IgA-VCA as a 
useful and worldwide method to diagnose NPC, and it is also used to anticipate 
recurrences after therapy (Zeng et al., 1985; de-Vathaire et al., 1988).   
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1.2.6.1.2 Other EBV antibodies in NPC patients  
The current standard method to diagnose NPC by IFA has been proven to be useful, 
but this method is not convenient to be used. It requires a certain amount of expertise, is 
labour-intensive, subjective and semi-quantitative. Using enzyme linked immunosorbent 
assay (ELISA) to detect the EBV specific antibodies becomes a new method to diagnose 
NPC (Chan et al., 2003).  
By ELISA test, anti-BZLF1 IgG was reported to be detected in most NPC 
patients and seldom in health carriers, but some other reports show that this antibody also 
appeared in other EBV-associated diseases such as IM, HD and BL (Mathew et al., 1994; 
Drouet et al., 1999). So the value of anti-BZLF1 antibody in diagnosis of NPC needs to 
further study.  
BMRF1 encodes EBV DNA polymerase accessory protein which forms part of 
EA-D component. IgA antibodies against BMRF1was found specifically in saliva and 
serum samples of NPC patients (Nadala et al., 1996). BXLF1 encodes EBV thymidine 
kinase (TK) which is a component of EA-R complex. IgG and IgA antibodies against 
TK was found in most sera of NPC patients, and interestingly IgA antibody seems 
specific appeared in NPC patients (Littler et al., 1990). BALF5 encodes EBV DNA 
polymerase which is also a component of EA complex. By Western blot analysis, 
moderate to high concentration of IgG specific antibodies against this protein were 
detected in most NPC sera and only in a small proportion of healthy EBV carriers (Lin 
et al., 1995). Together with the antibodies against BRLF1 and BGLF5 in NPC patients 
as we discussed before, all these antibodies seems have the potential to become markers 
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for early diagnosis of NPC. Some experiments have been done to evaluate the clinical 
value of these proteins. It seems that anti-TK and anti-DNase has great potential to be 
used for early diagnosing NPC, but these results need further confirmation (Littler et al., 
1991; Liu et al., 1997).  
 
1.2.7 Treatment           
      NPC is a relatively radiosensitive tumour and thus radiation therapy is the 
standard treatment for almost all NPC patients. For early stage NPC patients, the local 
control rates is about 70%-80% after radiotherapy, but for higher advanced stage 
patients the outcome is worse with 20–40% failure rates and a higher risk of distant 
metastases (Sham et al., 1990). Except radiotherapy, chemotherapy is also used to treat 
NPC, though it is not the main treatment. NPC type II and type III have been shown to 
be sensitive to chemotherapy, and in some cases NPC can be locally controlled by 
chemotherapy alone (Cvitkovic, 1997). In order to improve the treatment outcome, 
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1.3 OBJECTIVES OF THIS STUDY  
As discussed in the previous sections, NPC is consistently associated with EBV 
infection, and EBV genes may have some important functions in the development of 
NPC. Many studies have been done to investigate the EBV latent genes expression and 
their involvement in NPC. In contrast to the extensively studied EBV latent genes, EBV 
lytic genes expression and their possible contribution to the development of NPC is 
poorly understood. More and more data suggest the expression of some EBV lytic genes 
in NPC. However, there has never been a comprehensive study of EBV gene expression 
in NPC.  
The aims of this study are:   
1. To construct a reliable profiling system which can detect the RNA expression of all 
EBV genes.  
2. To comprehensively study the EBV gene expression pattern in NPC biopsies by using 
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2.1 SUBJECTS AND SAMPLES 
      10 NPC and 4 non-NPC nasopharyngeal tissue samples were included in this 
study. All the NPC patients were diagnosed as NPC based on histopathologic 
examination, and were recruited from Mount Elizabeth Medical Centre from 2002 to 
2003. All biopsies are kept in RNAlaterTM Stabilization Reagent (QIAGEN) and stored 
at -20℃ until use.  
 
2.2 CELL CULTURE TECHINIQUES 
2.2.1 Maintenance of cell line 
EBV-positive cell lines B95-8, Raji, P3HR-1, C666-1 and EBV negative cell line 
BJAB were used in this study. B95-8, Raji and P3HR-1 are all lymphocyte cell lines. 
B95-8 and P3HR-1 cells are permissive for productive EBV replication with small 
number of cells spontaneously entering the lytic cycle, while Raji cells are not 
permissive for EBV replication. C666-1 cell line is a subclone of its parental cell line, 
C666, derived from an NPC xenograft of southern Chinese origin. This epithelial cell 
line consistently carries the EBV in long-term cultures. EBV genome negative Burkitt’s 
lymphoma cell line BJAB was used as a negative control in this study.  
      All the cells were maintained in RPMI 1640 growth medium (Gibco BRL, 
Bethesda, MD) supplemented with 10% Fetal calf serum (FCS). The cells were kept in 
tissue culture flasks at 37℃ in a humidified CO2 (5%) incubator. Cells were fed every 3 
days or split whenever they grew too dense. For suspension cell lines (B95-8, Raji, 
P3HR-1 and BJAB), about 3/4 volume of old medium was removed and replaced with 
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the same volume of warmed, fresh growth medium. For adherent cell line C666-1, cells 
were treated with about 1/10 volume of trypsin after removal of old medium, and mixed 
with fresh growth medium to inactivate the trypsin. About 1/3 volume of the mixture 
was then transferred into a new flask containing warmed, fresh growth medium.    
 
2.2.2 Induction of EBV lytic cycle in cell lines 
B95-8, Raji, C666-1 and P3HR-1 cells were grown to the logarithmic phase. 
After cell counting and viability checking, the suspension cells (B95-8, Raji and 
P3HR-1) were resuspended to a density of 0.3×106 cells/ml with equal volume of fresh 
and original medium. Then, the phorbol ester 12-O-tetradecanoylphorbol-13-acetate 
(TPA) and n-butyrate (Sigma) were added to final concentration of 20ng/ml and 3mM 
respectively. For adherent cell line (C666-1), when the cell confluence was about 60%, 
the medium was renewed, and TPA and n-butyrate were added to the final concentration 
of 20ng/ml and 3mM, respectively. The cell culture was gently swirled to mix the 
chemicals, and cultured at 37℃ in a humidified CO2 (5%) incubator for 3 days without 
feeding until harvested.  
       
2.3 MOLECULAR TECHNIQUES  
2.3.1 Primers  
To detect the RNA expression of EBV genes, we synthesized the primers for all 
EBV genes. Based on EBV DNA sequence of B95-8 strain (database accession number 
NC_001345), we designed the primers by using Vector NTI Suite 7 program. For the 
                                                           Materials & Methods                  
                                                                                        - 43 - 
genes which are deleted in B95-8 EBV strain, we designed the primers based on the 
EBV DNA sequence of Raji strain (database accession number M35547).  
The primer designs were based on the following criteria:  
1. The Tm of every primer was in the range of 60-62℃.  
2. The primers did not form stable secondary structure, homo or hetero dimers.  
3. The amplicon size was in the range of 300-800bp.  
4. The amplicon location was within 1kb upstream of poly-adenylation signal 
except for the amplicons that encompass splice signals, because in oligo-dT-primed 
reverse transcription, the sequence too far upstream of poly-adenylation signal is not 
efficiently reverse transcribed.  
5. Protein-coding sequences were preferred, because sequence variations among 
different EBV strains are less in protein-coding regions than in non-coding regions.   
6. For spliced genes, additional primers were designed to amplify the sequences 
across the introns.   
The sequences of primers are listed in Appendix 1, and all primers were 
synthesized by Research Instruments Singapore Pte Ltd. 
 
2.3.2 Total RNA/DNA extraction 
Total RNA and DNA were extracted simultaneously from cell lines and frozen 
biopsies using RNA/DNA isolation kit (QIAGEN). About 4×106 cells of every cell lines 
or 20mg of every tissue samples were used every time. The procedure described in the 
QIAGEN RNA/DNA Handbook was followed. To isolate nucleic acids from the 
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preserved tissue, the tissue was first placed in liquid nitrogen, and grounded with a 
mortar and pestle. The tissue power was then solubilized in the lysis buffer supplied 
with the kit and homogenized by passing through a G26 needle. The purity and 
concentration of extracted RNA or DNA were determined by spectrophotometry using a 
GeneQuant RNA/DNA calculator (Biochrom Ltd.). The integrity of RNA or DNA was 
checked using agarose gel electrophoresis.    
 
2.3.3 Removal of decontaminating DNA from RNA  
     To eliminate the DNA contamination from RNA, all RNA samples were treated 
with RNase-free DNase I (QIAGEN). 5 Kunitz units of DNase I was used to treat 10μg 
of extracted RNA in the final volume of 20μl reaction mixture containing 1×reaction 
buffer (50mM NaCl, 10mM Tris-HCl, 10mM MgCl2, 1mM dithiothreitol; PH 7.9). The 
mixture was incubated at 37℃ for 30 min, and then was heated at 72℃ for 5 min to 
inactivate the DNase I. The effect of DNase I treatment was checked by PCR.  
 
2.3.4 Reverse Transcription        
     cDNA was synthesized from RNA by using Omniscript Reverse Transcriptase Kit 
(QIAGEN) according to the manufacturer’s instruction. Briefly, the 1st strand cDNA 
was synthesized in total volume of 100μl reaction mixture containing 1×reaction buffer 
(proprietary), 0.5mM of each dNTP, 1μM oligo-dT15 primer, 50 units RNase inhibitor, 
20units Omniscript Reverse Transcriptase and 10μg template RNA. The reaction was 
performed by incubating at 37℃ for 60 min, and followed by heating to 93℃ for 5 min 
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PCR reaction was performed by using HotStarTaq Polymerase (QIAGEN), 
according to the HotStarTaq PCR handbook. 1μl of synthesized cDNA was added into a 
final volume of 30μl PCR reaction mixture containing 1×PCR buffer (Tris-Cl, KCl, 
(NH4)2SO4, 15mM MgCl2; PH 8.7), 200μM of each dNTP, 0.2μM of each primer and 
0.75 units HotStarTaq DNA polymerase. After heating to 95℃ for 15min to activate the 
polymerase, the amplification was carried out for 35 cycles with each consisting of 
94℃ for 45 sec, 60℃ for 45 sec, and 72 ℃ for 2 min. At last, the mixture was heated to 
72 ℃ for 10 min and then cooled to 4℃. When DNA was used as template to do PCR, 
20ng of total DNA from EBV cell lines or NPC biopsies or 100ng of DNA from 
non-NPC tissues was added into each reaction. When RNA was used as the template for 
a negative control, 0.1μg RNA was added into each reaction.   
 
2.3.6 One-Step RT-PCR 
One-Step RT-PCR was done using the QIAGEN OneStep RT-PCR kit, according 
to the manufacturer’s instruction. 2μg DNase I treated RNA was added to the total 
volume of 50μl reaction mixture containing 1×QIAGEN OneStep RT-PCR buffer 
(Tris-Cl, KCl, (NH4)2SO4, 12.5mM MgCl2, DTT; PH 8.7 ), 400μM of each dNTP, 0.6 
μM of each of the gene-specific forward and reverse primers, 2.0μl QIAGEN OneStep 
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RT-PCR enzyme Mix and 10 units of RNase inhibitor. First the mixture was incubated 
at 50℃ for 30 min to synthesis the 1st strand cDNA, and followed by heating to 95℃ 
for 15 min to inactivate the reverse transcriptase. Second, the amplification was carried 
out for 35 cycles with each consisting of 94℃ for 45 sec, 60℃ for 45 sec, and 72 ℃ for 
2 min. Finally, the mixture was heated to 72 ℃ for 10 min and followed by cooling to 
4℃.  
To test the direction of transcript, forward or reverse primer was omitted from the 
reaction mixture in the initial reverse transcription step (the step for incubation at 50℃ 
for 30 min). After heating of the reaction mixture at 95℃ for 15 min to inactivate the 
reverse transcriptases, the omitted primer was added back into the mixture, and the 
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3.1   PART 1: TESTING OF PRIMERS 
In order to find what EBV genes are expressed in NPC biopsies, we constructed a 
profiling system. This system is based on RT-PCR techniques to detect the EBV RNA 
expression in NPC biopsies. We designed primers for every EBV gene and used DNA 
and RNA from different EBV-infected cell lines to test the primers. 
 
3.1.1 Testing of primers  
To test the amplification efficiency and specificity of the designed primers, we 
extracted DNAs from different cell lines and used them in PCRs. We chose four 
EBV-positive cell lines, including B95-8, C666-1, Raji, P3HR-1, and one EBV-negative 
lymphocyte cell line BJAB as a negative control for EBV gene amplification. Parts of 
the testing results are shown in Fig. 3.  
As shown on Fig. 3, PCR products of expected sizes were amplified from most 
EBV cell lines. Neither EBV negative nor positive cell lines showed non-specific PCR 
products. This showed that most primers amplified EBV specific sequences from 
different EBV strains and non-specific amplification of cell genes was absent. For the 
primers that were unable to amplify EBV genes from all tested EBV strains, we 
redesigned new ones until we found the primers that served the purpose. For example, 
the primers for BBLF2 did not amplify the EBV DNA from Raji cells (as shown in 
Fig.3, BBLF2 lane 3). Therefore they were redesigned until they amplified EBV 
specific sequences from four EBV strains successfully (data not shown). 
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Fig. 3 Testing of EBV-gene specific primers (partial results). 
PCRs were performed using the primers specific for EBV genes shown on the top of each panel, 
and the whole cell DNA of B95-8, Raji, P3HR-1, C666-1 and BJAB cells (lanes marked from 1 
to 5 respectively) as the template. The products were electrophoresced on 1% agarose gel. Lane 
marked M contain 100bp DNA marker with sizes indicated on the left.  
Predicted sizes of PCR products of the twelve EBV genes: BBRF1: 583bp; BBRF2:649bp; 
BBLF3:480bp; BBLF2:671bp; BBRF3:661bp; BGLF5:657bp; BGLF4:663bp; BGLF3:581bp; 
BGLF2:628bp; BGLF1: 716bp; BDRF1:635bp; BDLF4: 447bp. 
 
Because the EBV DNA variations exist in different EBV strains (Bornkamm et 
al., 1980), DNAs from four different EBV cell lines were used to test the primers in this 
study, and an EBV genome negative Burkitt’s lymphoma cell line (BJAB) was used as a 
negative control. Based on the testing results, we can make a conclusion that our 
primers can work well to detect EBV genes from different EBV strains.  
 
M  1  2  3  4  5  1  2  3  4  5  1  2  3  4  5  1  2  3  4  5  1  2  3  4  5  1  2  3  4  5  
       
BBRF1    BBRF2     BBLF3     BBLF2     BBRF3    BGLF5 
     BGLF4     BGLF3    BGLF2    BGLF1    BDRF1     BDLF4 
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3.1.2 Total RNA extraction, DNase I treatment and Reverse Transcription 
By using QIAGEN RNA/DNA isolation kit, total RNA and DNA was isolated 
from about 4 x 106 B95-8, C-666, Raji and P3HR-1 cells with/ without TPA induction. 
The products were analyzed using agarose gel electrophoresis. Typical results were 
shown in Fig. 4. The appearance of the RNA and DNA preparations suggested that the 
extracted RNA and DNA were intact.   
 
 
      Fig. 4 Analysis of RNA and DNA extracted from B95-8 cells without TPA 
induction. The RNA and DNA preparations which extracted form B95-8 cells were 
electrophoresced on 1% agarose gel. Lane marked M contain 1Kb DNA marker with 
sizes indicated on the left. 
 
The total RNA was treated with DNase I to eliminate the DNA contamination, 
and then about 10 μg of each DNase I treated RNA sample was used for cDNA 
synthesis in 100 μl reaction. 
To verify that the RNA was free of DNA contamination and that the cDNA 
synthesis was successful, we performed PCR-amplification of GAPDH gene sequence 
using the following samples as the template: (ⅰ) purified RNA without treated by 
DNase I, (ⅱ) DNase I treated RNA, and (ⅲ) cDNA synthesized from DNase I treated 
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RNA. The results are shown in Fig. 5.     
        
                                       
Fig. 5 Analysis of cDNA quality.  
GAPDH amplifying PCR was performed using the following samples as template  
(1) B95-8 cell RNA without DNase I treatment. (2) B95-8 cell RNA with DNase I treatment. 
(3) cDNA synthesized from DNase I treated B95-8 cell RNA.  
Lane marked M contain 100bp DNA marker with sizes indicated on the left. The size of 
specific PCR product indicated on the right.       
 
Cellular gene GAPDH encodes Glyceraldehyde-3-phosphate dehydrogenase 
which is a glycolytic enzyme that catalyzes the conversion of 
glyceraldehyde-3-phosphate to 1, 3-diphosphoglycerate. This gene is constitutively 
expressed in almost all tissues at high levels, and its RNA is commonly used as an 
invariant control in studies of gene expression (Yajima et al., 1998). We chose this gene 
to test the effect of DNase I treatment, and the result of cDNA synthesis. As seen from 
Fig. 5, a PCR product was obtained from purified RNA (lane 1) indicating that the RNA 
was contaminated with cellular DNA. No PCR product was obtained from DNase I 
treated RNA (lane 2) indicating that the contaminating DNA in the RNA preparation 
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had been reduced to an undetectable level through DNase I treatment. A strong PCR 
product was obtained from the cDNA synthesized from DNase I-treated RNA (lane 3). 
This showed that the cDNA synthesis was successful, and that the PCR product was 
derived entirely from cDNA but not from contaminating DNA in the RNA preparation.  
We regularly performed the same analysis for all samples derived from cell lines 
or nasopharyngeal tissues before subjecting the cDNA preparations to amplifications of 
EBV genes to make sure that the RT-PCR products obtained were indeed derived from 
RNA.       
 
3.1.3 EBV RNA profiles of EBV cell lines 
3.1.3.1 B-lymphocyte-derived cell lines 
In order to test whether our set of primers can be used to profile EBV RNAs, we 
used them to amplify cDNA prepared from different EBV-infected cell lines whose 
EBV RNA patterns had been documented.  
Generally, continuous cell lines established by EBV infection carry the virus 
genome in a latent state. Several agents have been identified that can disrupt latency in 
those cell lines. TPA is one of the agents (zur Hausen et al., 1978). EBV transformed 
marmoset lymphocyte cell line B95-8 can enter lytic cycle and produce infectious virus, 
but only a minority of cells can spontaneous enter lytic cycle (about 5%-10%). 
Treatment B95-8 with TPA can efficiently increase the number of virus-producing cells 
(Hudewentz et al., 1980). Human Burkitt’s lymphoma cell line P3HR-1 is also virus 
producing cell line. Like B95-8 cells, small proportion of cells (1-3%) can enter the 
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lytic cycle spontaneously. Treatment with TPA considerably elevates the number of 
virus-producing cells (Kurakata et al., 1989). Unlike B95-8 and P3HR-1 cell lines, 
human Burkitt's lymphoma cell line Raji cannot produce virus even after TPA induction. 
The early stage of the viral cycle can be induced after treatment with TPA, but viral 
DNA synthesis is completely inhibited, consequently it is impossible for this cell line to 
produce viral particles. Some data show that EBV EA expression can be induced by 
TPA, but VCA cannot (Fresen et al., 1978). Absence of BALF2 gene expression may 
cause the inhibition of productive lytic cycle in Raji cell (Decaussin et al., 1995). The 
EBV gene expression patterns of B95-8, P3HR-1 and Raji cell lines without and with 
induction have been studied before (Hummel et al., 1982; Weigel et al., 1983; 
Anisimova et al., 1982). Therefore, cDNAs from uninduced and induced cells of these 
cell lines were used as the templates to test our EBV primers.   
The results are shown in Fig. 6 and the EBV RNA patterns of different cell lines 
were listed in Table 3. In order to achieve a semi-quantitative measurement of relative 
RNA level of most EBV genes, we used an amount of cDNA template for PCR such 
that the amounts of PCR products for these EBV genes were in positive relationship 
with the amount of input cDNA (Freeman et al., 1999). As such, we distinguished four 
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Table 3. EBV gene expression pattern in different cell lines  
 






























1 GAPDH cellular  454 +++ +++ +++ +++ +++ +++ +++ +++
2 BNRF1 late 712 + ++ -  -  - - +/-  + 
3 BCRF1 late 510  + ++  - - - -  +/- ++ 
4 BCRF2 unknown 551 - + - - - +/- ++ ++ 
5  EBNA-LP(SJ) latent 103/187 +/- -  -  -  +/- - - - 
6 EBNA2 latent 706 ++ ++ - - +/- +/- - - 
7 BHLF1 early  237 +++ +++ +++ +++ ++ +++ - - 
8 BHRF1(SJ) early 588/997 ++ +++ - +/- - ++ - ++ 
9 EBNA2(SJ) latent  388/859 ++ +/- - - + +/- - - 
10 BFLF2 early 606 + +++ - +/- - ++ ++ ++ 
11 BFLF1 early 667 +/- +/- - - - +/- +/- +/- 
12 BFRF1 early/late 696 +/- +/- - - - - +/- +/- 
13 BFRF2  early/late 666 - +/- - +/- - +/- +/- + 
14 BFRF3 early/late 458 + +++ + ++ +/- ++ ++ +++
15 BPLF1 unknown 394 ++ ++ +/- +/- - - +/- ++ 
16 BOLF1 unknown 706 - - - - - - - - 
17 BORF1 late 681 +/- + - +/- - +/- +/- + 
18 BORF2 early 682 ++ +++ + +++ +/- ++ ++ +++
19 BaRF1 early 668 +/- + +/- +/- - + + ++ 
20 BMRF1 early 708 ++ +++ ++ +++ +/- ++ ++ +++
21 BMRF2 late 547 +++ +++ +++ +++ +/- +++ ++ +++
22 BMLF1 early 673 ++ +++ ++ +++ +/- +++ ++ +++
23 BSLF2- 
BMLF1(SJ) 
early 413/517 +/- ++ +/- ++ - ++ + ++ 
24 BSLF1 early 544 + ++ +/- + +/- + ++ ++ 
25 BSRF1 late 657 +/- +  - +/- - + +/- ++ 
26 BLLF3 early 729 +/- +/- - +/- - + - + 
27 BLRF1 late 304 ++ +++ +/- + - + + +++
28 BLRF2 late 411 ++ ++ + ++ - + + ++ 
29 BLLF2 early 520 ++ ++ +/- +/- - +/- +/- ++ 
30 BLLF1(SJ) late 364/983 ++ ++ - +/- - + +/- ++ 
31 EBNA3A latent 621 +/- ++ - - +/- +/- - - 
32 EBNA3B(SJ) latent 550/628 +/- ++ - - - +/- +/- ++ 
33 EBNA3B latent 394 ++ +++ +/- +/- +/- +/- + ++ 
34 EBNA3C(SJ) latent 605/678 - - - - - - - - 
35 EBNA3C 3’ latent 648 +/- + - - - - - - 
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Table 3. EBV gene expression pattern in different cell lines (continued) 
 






























36 BZLF2 late 598 +/- + - - - - - +/- 
37  BZLF1(SJ) early 558&663
/871 
++ +++ ++ ++ - ++ + +++
38 BRLF1 early 616 +/- + - +/- - + +/- ++ 
39 BRLF1- 
BZLF1(SJ) 
early 742/3000 - +/- - +/- - +/- - +/- 
40 BRRF1 early 651 ++ +++ +/- ++ + ++ + +++
41 BRRF2 late 732 ++ ++ +/- + +/- + + ++ 
42 EBNA1 latent 666 ++ ++ ++ ++ ++ ++ ++ + 
43 BKRF2 late 334 + +++ +/- +/- +/- + + +++
44 BKRF3 unknown 534 + ++ +/- ++ +/- +/- +/- ++ 
45   BKRF4 early 454 ++ +++ +/- ++ +/- ++ + +++
46 BBLF4 early 711 +/- ++ +/- ++ - ++ +/- ++ 
47 BBRF1 late 583 + ++ - - +/- + +/- ++ 
48 BBRF2 late 649 ++ +++ +/- + +/- + + +++
49 BBLF3 early 480 +++ +++ +/- ++ - ++ + +++
50 BBLF2 early 522 + ++ - + - + + ++ 
51 BBLF2(SJ) early 624/752 ++ ++ +/- + - ++ + ++ 
52 BBRF3 late 661 ++ ++ +/- + - + + ++ 
53  BBLF1 late 209 +++ +++ +++ +++ +/- +++ ++ +++
54 BGLF5 early 657 +/- + +/- + + ++ +/- ++ 
55 BGLF4 early 663 + ++ +/- +/- - + +/- ++ 
56  BGLF3 unknown 581 +/- + +/- +/- - +/- +/- ++ 
57 BGRF1- 
BDRF1(SJ) 
late 616/4500 +/- + - +/- - +/- +/- ++ 
58 BGLF2 late 628 + ++ - +/- - + +/- ++ 
59 BGLF1 late 716 +/- + - +/- - - +/- + 
60 BDLF4 early 447 +/- ++ - +/- +/- + +/- + 
61 BDRF1 late 635 +/- ++ - +/- - + +/- ++ 
62 BDLF3 late 652 ++ +++ - - - - +/- ++ 
63 BDLF2 late 504 ++ ++ - - - - +/- ++ 
64 BDLF1 late 652 + ++ - - - - +/- + 
65 BcLF1 late 628 + ++ - - - - +/- ++ 
66 BcRF1 early 729 - +/- - - - - - +/- 
67 BTRF1 late 643 - +/- - - - - - +/- 
68 BXLF2 late 675 ++ +++ +/- ++ - ++ +/- +++
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Table 3.  EBV gene expression pattern in different cell lines (continued) 
 






























69 BXLF1 early 673 +/- +/- - +/- - +/- +/- +/- 
70 BXRF1 late  612 +/- + - - - - +/- + 
71 BVRF1 early 708 + +++ +/- ++ - ++ + +++
72 BVRF2 late 623 +/- + - - - - +/- + 
73 BdRF1 late 686 +++ +++ +/- + - ++ ++ +++
74 BILF2 late 565 +++ +++ +/- + - ++ ++ +++
75 BILF1 5 ’ unknown 603 +/- + +/- +/- - + +/- + 
76 RJLF3 early 178 - - +/- +/- - ++ - ++ 
77 RJLF2 unknown 676 - - + ++ - ++ + +++
78 RJLF1 unknown 774 - - - - - - - - 
79 BILF1 unknown 607 ++ ++ ++ ++ +/- ++ + ++ 
80 BALF5 early 655 +/- + +/- + - + +/- + 
81 ECRF4 unknown 636 + + + +/- +/- + +/- + 
82 BALF4 late 626 +++ +++ + ++ +/- +/- +/- +++
83 BART1(SJ) latent 690/5000 - - - - - - - - 
84 BART2(SJ) latent 773/1802 +/- + + +/- +/- + +/- +/- 
85 BART3(SJ) latent 939/1110 - - - - - - - - 
86 BALF3 unknown 674 - - - - - - - - 
87 BALF2 early 586 +/- + - + - - +/- + 
88 BALF1 early 686 +/- ++ - +/- - - +/- + 
89 BARF1 early 608 + ++ +/- ++ - - +/- ++ 
90 BNLF2 late 497 ++ ++ +/- + ++ ++ ++ ++ 
91 LMP1 3’ latent 692 + ++ - - ++ + + + 
92 LMP1 3’(SJ) latent 405/481 ++ +++ - - ++ + +/- ++ 
93 LMP1 5’(SJ) latent 633/788 + ++ - - + +/- +/- +/- 
94 LMP2A 5’ latent 256 + + - - - +/- +/- +/- 
95 LMP2B 5’ latent 119 +/- +/- - - - +/- - - 
96 LMP23’(SJ) latent 694/5000 ++ ++ +/- + ++ ++ ++ +++
*According to intensity of PCR products, the PCR products were classified into four groups: +/-: 
weak band; +: clear band; ++: strong band; +++: very strong band.    
*Bu: B95-8 cell without TPA induction; Bi: B95-8 cell with TPA induction; Cu: C-666 cell without 
TPA induction; Ci: C-666 cell with TPA induction; Ru: Raji cell without TPA induction; Ri: Raji 
cell with TPA induction; Pu: P3HR-1 cell without TPA induction; Pi: P3HR-1 cell with TPA 
induction.  
*SJ: Sequences across spliced region. The predicted sizes of PCR products of spliced and unspliced 
transcripts are indicated before and after / respectively. 
*For the PCR product across spliced region, we only show the spliced product in this table.  
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The first gene we detected was GAPDH, a cellular gene which was used as an 
invariant control in this study. The intensities of the PCR products of GAPDH from 8 
different samples (Fig. 6, lanes 1a-1h) were similar. We roughly estimated that the cell 
numbers for every PCR reaction were similar.  
In B95-8 cells, we detected RNA expression of most EBV genes, and the 
expression patterns were different between before and after TPA induction. For latent 
genes, B95-8 cell without TPA induction expressed RNAs of EBNA1, EBNA2, 
EBNA3s, EBNA-LP, LMP1, LMP2A, LMP2B and BARTs (as shown in Fig. 6, lanes 
42a, 9a, 31a, 33a, 35a, 5a, 91a, 94a, 95a and 84a respectively). In our profiling system, 
we did not detect the RNAs of EBV EBERs, because it is nonpolyadenylated, 
noncoding RNAs. Our profiling method using oligodT-primed cDNA synthesis cannot 
detect nonpolyadenylated RNAs. Using separate one-step RT-PCRs with gene-specific 
primers, we detected the transcripts of EBERs both in EBV cell lines and NPC biopsies 
(data not shown). Based on our profiling results, all EBV latent genes were expressed in 
B95-8 cells, and this expression pattern belonged to latency type III. This result was 
consistent with previous studies (Young et al., 2000).  
After TPA induction, the spliced form transcripts of two latent genes EBNA-LP 
and EBNA 2 were decreased clearly and the unspliced form of the two genes were 
increased (as shown in Fig. 6, lanes 5a, 5b and 9a, 9b). Because only the spliced 
transcripts can give rise to proteins, we deduced that the 2 latent proteins were 
decreased after cell entering the lytic cycle. This expression change consisted with 
previous report that the expression of EBV latent proteins was repressed when EBV got 
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into lytic cycle (Kenney et al., 1989). The unspliced transcripts of some other latent 
genes also increased, such as EBNA3A, EBNA3B and EBNA3C (as shown in Fig. 6, 
lanes 31a and 31b, 33a and 33b, 35a and 35b).The increase in unspliced transcripts of 
latent genes could be caused partly by the expression of EBV SM lytic protein which 
can activate intronless genes expression and inhibit expression of intron-containing 
genes (Ruvolo et al., 1998). It also could be partly due to the increased DNA template 
resulted from the DNA replication upon induction.   
For lytic genes, we can detect most transcripts before induction, but their levels 
were low. After induction, transcripts of most lytic genes increased greatly. This result 
indicated that a small percentage of spontaneous lytic cells existed in an uninduced 
B95-8 culture, and treatment with TPA greatly increased the lytic cell number. This 
gene expression pattern in B95-8 cells consisted with other reports (Hummel et al., 
1982). Only a few transcripts of lytic genes are spliced. Unlike latent genes, the spliced 
transcripts of lytic genes were increased upon induction, such as lytic gene BHRF1 (as 
shown in Fig.6, lanes 8a and 8b). It suggested that the expression of EBV lytic proteins 
increased upon induction and the cells got into the lytic cycle. Based on our profiling 
results on B95-8 cells, our profiling system could detect RNAs of most EBV genes and 
correctly reflected the RNA expression change between uninduced and induced B95-8 
cells.     
In P3HR-1 cells, before TPA induction we detected RNAs of five latent genes, 
including: EBNA1, EBNA3B, LMP1, LMP2A and BARTs (as shown in Fig. 6, lanes 
42g, 33g, 91g, 94g and 84g respectively) , and very low level RNAs of lytic genes. The 
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very low level RNAs of lytic genes might come from the P3HR-1 cells which 
spontaneously entered lytic cycle, and its expression level was generally lower than in 
B95-8 cells without TPA induction indicating that lower percentage of P3HR-1 cells 
spontaneously entered lytic cycle. For example, RNAs of lytic genes BLLF2 and 
BcLF1 in uninduced P3HR-1 cells was less than in uninduced B95-8 cells (as shown in 
Fig. 6, lanes 29g and 65g). This result consisted with previous reports about these two 
EBV cell lines (Kurakata et al., 1989; Hudewentz et al., 1980).  
After induction, the RNAs of most EBV lytic genes were detected including some 
RNAs which were not detected before induction, and the expression level increased 
greatly. For example, the RNA of lytic gene BLLF3 was detected only after induction 
(as shown in Fig 6. lane 26h). It demonstrated that more P3HR-1 cells got into lytic 
cycle after induction. Our results are consistent with the results of previous studies 
about EBV RNA expression in P3HR-1 cells without and with TPA induction (Weigel et 
al., 1983), again showing that our profiling system was suitable for detect EBV RNAs 
in P3HR-1 cells.  
Raji cell line is different form B95-8 and P3HR-1 cell lines; it is a nonproducer 
Burkitt’s lymphoma cell line (Fresen et al., 1978). After TPA induction, EBV early 
antigens (EA) are expressed in Raji cells, but no EBV VCA synthesis and no viral 
particle production (Anisimova et al., 1982). Our study got the same results as previous 
study. Before TPA induction, Raji expressed some latent genes including: EBNA1, 
EBNA2, EBNA3A, EBNA3B, EBNA-LP, LMP1 and BARTs (as shown in Fig. 6, lanes 
42e, 9e, 31e, 33e, 5e, 91e and 84e respectively). Very low level RNAs of less than 1/3 
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lytic genes were detected. It suggested that only very small numbers of Raji cells 
spontaneously entered the lytic cycle.  
After induction, transcripts of about 80% lytic genes were detected, including the 
genes which encode the EBV EA components, such as BMRF1 which encodes early 
antigen diffuse components (EA-D) (as shown in Fig. 6, lane 20f). However, not all 
transcripts of early genes were detected. For example, RNA of early gene BALF2 which 
encodes a DNA binding protein was not detected (as shown in fig 6. lane 87f). This 
result is consistent with other reports that EBV early lytic genes could be efficiently 
induced by TPA (Anisimova et al., 1982; Decaussin et al., 1995).   
The RNAs of some EBV lytic late genes were detected after induction, but the 
expression level was low, and generally lower than in B95-8 and P3HR-1 cells. 
Transcripts of many late genes were not detected, including the genes which encode the 
EBV VCA components. For example, RNA of BcLF1 which encodes the structural 
nucleocapsid protein that is one of the major components of VCA was not detected in 
Raji cells (Fig. 6, lanes 65e and 65f). Expression of BcLF1 usually indicates the 
completion of EBV lytic cycle (Rickinson & Kieff, 1996). This result indicated that Raji 
cells did not complete lytic cycle nor produce viral particles even after TPA induction. 
These cells seemed stay in an abortive lytic stage. This was in accordance with previous 
studies (Polack et al. 1984; Anisimova et al., 1982).  
The profiling results of the three different EBV-positive cell lines (B95-8, 
P3HR-1 and Raji) showed that our profiling system detected transcripts of most EBV 
genes in different cell lines, and correctly reflected the gene expression change before 
                                                         Results & Discussions                   
                                                                                        - 69 - 
and after induction. Compared with previous studies, our profiling results were 
consistent with them. All these suggest that our profiling system can work well to detect 
transcripts of EBV genes in different EBV cell lines, and can be used for profiling EBV 
gene expression in NPC cells. 
 
3.1.3.2 NPC-derived cell line C666-1 
Epithelial cell line C666-1 is a new EBV infected cell line. It is derived from the 
NPC xenograft and consistently carries EBV in long-term cultures (Cheung et al., 1999). 
This cell line can be used as a model to study NPC tumour cells. Unlike other 
EBV-positive B-lymphocyte-derived cell lines which were used in this study, the EBV 
gene expression of this cell line has not been well studied. Previous research just 
studied the latent genes expression. EBNA 1 protein and transcripts of BARTs, LMP1 
and LMP2 are expressed (Cheung et al., 1999; de Jesus et al., 2003). We chose this 
epithelial cell line as a prelude to the study of the EBV gene expression in NPC tumour 
cells. 
Our profiling results showed that RNAs of three latent genes were detected in 
C666-1 cells without induction, including EBNA1, LMP2 and BARTs (as shown in Fig 
6. lanes 42c, 96c and 84c respectively). Transcript of LMP1 was not detected in our 
study. This result is inconsistent with previous study which showed expression of EBV 
LMP1 in this cell line (Cheung et al., 1999). This could be due to the different methods 
we used to detect EBV RNA. Cheung’s study used nested PCR plus probe hybridization, 
a more sensitive method than ours, to detect LMP1 RNA. They detected a very low 
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level of LMP1 transcript. However their western blot analysis was unable to detect 
LMP1 protein. It is likely that the RNA expression level of LMP1 is very low in C666-1 
cells so that it cannot be detected in our method. It is not possible for us to use such a 
highly sensitive but tedious method to detect RNAs of all EBV genes. Moreover, 
extreme low levels of RNA expression which can only be detected by this highly 
sensitive method may not be physiologically significant. Based on our results, latent 
gene expression in this cell line seems belong to latency type I/II which is typical of 
NPC cells (Kieff & Rickinson, 2001).    
For lytic genes, transcripts of more than half lytic genes were detected before 
induction, but the expression level was very low except 3 lytic genes BHLF1, BBLF1 
and BMRF2 (as shown in Fig. 6, lanes 7c, 53c and 21c respectively), which were 
expressed at very high level.  
Though transcripts of more than half lytic genes were expressed in C666-1 cell 
without induction, transcripts of many EBV lytic late genes were not detected. TPA 
induction increased transcripts of many EBV lytic genes in C666-1 cells. However, 
transcripts of more than 20% lytic genes were not detected even after induction, 
including late gene BcLF1 (as shown in Fig. 6, lane 65d) which codes for the major 
capsid protein. It showed that C666-1 cell line could not complete the lytic cycle and 
produce viral progeny even after TPA induction. EBV in C666-1 cells seemed to stay in 
an abortive lytic stage like in Raji cells. Comparing the RNA expression in C666-1 cells 
with Raji cells without induction, we found more EBV lytic genes were expressed in 
C666-1 cells than in Raji cells (as shown in Table 3). However, less EBV genes were 
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induced by TPA in C666-1 cells such that TPA-treated C666-1 cells expressed less EBV 
genes than TAP-induced Raji cells (Table 3). It suggested that the lytic cycle is blocked 
by different regulatory mechanisms in the two cell lines.   
In summary, based on the profiling results of four EBV infected cell lines, our 
profiling system is suitable for detecting EBV RNAs in different EBV cell lines and is 
usable for profiling EBV gene expression in NPC cells. Profiling results on C666-1 cell 
line indicates that its resident EBV is in type I/II latency and is defective in lytic 
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3. 2 PART 2: TEST EBV GENE EXPRESSION IN NPC BIOPSIES 
3. 2. 1 DNA and RNA extraction  
Ten NPC and four non-NPC nasopharyngeal biopsies were investigated in our 
study. Total RNA and DNA were isolated from 20 mg of every tissue sample as 
described in section 2.3.2. The products were analyzed using agarose gel 
electrophoresis. We got the similar results as shown in Fig. 4. The appearance of the 
RNA and DNA preparations suggested that the extracted RNA and DNA from biopsies 
were intact. 
 
3.2.2 EBV DNA profiling of tissue samples  
Because we found that most EBV genes were not expressed in NPC biopsies 
after a preliminary study of tissue samples (data not shown), we omitted some genes 
that were never expressed in any of the preliminary samples and chose half of EBV 









                                                         Results & Discussions                   
                                                                                        - 73 - 



















1 GAPDH cellular 454 25 BKRF4 late 454 
2 BNRF1 late 712 26 BBLF4 early 711 
3 BCRF1 late 510 27 BBLF1 late 209 
4 EBNA- 
LP3’(SJ) 
latent 103/187 28 BGLF5 early 657 
5 EBNA2 latent 706 29 BGLF4 early 663 
6 BHLF1 early 237 30 BDLF4 early 447 
7 BHRF1 
5’(SJ) 
early 558/997 31 BDLF3 late 652 
8 EBNA2 
5’(SJ) 
latent 388/859 32 BcLF1 late 628 
9 BFRF3 early/late 458 33 BTRF1 late 643 
10 BORF2 early 682 34 BXLF2 late 675 
11 BMRF1 early 708 35 RJLF3 early 178 
12 BMRF2 late 547 36 RJLF2 unknown 676 
13 BMLF1 early 673 37 BILF1 unknown 607 
14 SM(SJ) early 413/517 
 
38 BALF5 early 655 
15 BLLF3 early 729 39 BART2 
(SJ) 
latent 773/1802 
16 BLRF2 late 411 40 BALF2 early 586 
17 BLLF1 
(SJ) 
late 364/983 41 BALF1 early 686 
18 EBNA 3A latent 621 42 BARF1 early 608 








21 BRLF1 early 616 45 LMP1 
5’(SJ) 
latent 633/788 
22 BRRF1 early 651 46 LMP2A latent 256 
23 BRRF2 late 732 47 LMP2B latent 119 
24 EBNA1 latent 666 48 LMP2 
3’(SJ) 
latent 694/5000 
*SJ indicated the PCR product across spliced region. The predicted sizes of PCR products of 
spliced and unspliced transcripts are indicated before and after / respectively. 
*latent: EBV latent gene; early: EBV lytic early gene; late: EBV lytic late gene; cellular: cell gene. 
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For each sample, we first tested whether our primers could amplify EBV 
sequences from the extracted DNA. For NPC biopsies, we used about 20ng DNA as 
template for each PCR. Fig. 7 shows the results of such an analysis of a typical NPC 
biopsy. In general, most primers efficiently amplified specific EBV sequences from 
NPC samples, and only occasional primers did not work well. For instance, for this 
particular NPC sample, primers for GAPDH and EBNA3C amplified gene specific 
sequences, but also amplified some non-specific sequences (as shown in Fig. 7, lanes 1 
and 19 respectively). Furthermore, primers for EBNA-LP, BHLF1 and LMP2B 
correctly amplified EBV sequences, but the amount of PCR products were less than 
others (as shown in Fig. 7, lanes 4, 6 and 47 respectively). This could be due to the 
variant EBV DNA sequences existing in different samples so that some primers could 
not work well in individual NPC biopsies. However, most primers successfully 
amplified EBV specific gene sequences in all NPC biopsies, and only a small number of 
primers did not work well in 1-2 of total 10 samples. So this problem should not affect 
significantly our interpretation of results. 
For non-NPC tissue samples, we used more DNA template (100ng) for each PCR. 
Fig. 8 shows the analysis results for a typical non-NPC sample. In general, more than 
half of the reactions could produce specific PCR products from a non-NPC tissue 
sample, but the amounts of EBV-specific PCR products were much less than those 
obtained from NPC biopsies. For this particular non-NPC sample, thirteen reactions did 
not give any signals, including EBNA-LP, EBNA2, BHLF1, BFRF3, BLLF3, EBNA3C, 
BKRF4, BTRF1, RJLF3, BART2, LMP1, LMP2B and LMP2 (as shown in Fig. 8, lanes 
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4, 5, 6, 9, 15, 19, 25, 33, 35, 39, 44, 47 and 48 respectively). Six reactions produced 
weak specific and non-specific products, including GAPDH, BNRF1, EBNA1, BBLF1, 
BILF1 and BALF4 (as shown in Fig. 8, lanes 1, 2, 24, 27, 37 and 41 respectively).  
Our results showed that the EBV DNA existed in normal nasopharyngeal tissues, 
but in extremely low levels. Though more DNA from non-NPC biopsies was used as 
template to do PCR, it gave no or less products than that from NPC biopsies. This 
should most likely be due to the small amounts of EBV DNA existing in non-NPC 
tissues. Previous studies reported that EBV genome was contained in all malignant 
epithelial cells, but always negative in untransformed squamous epithelia from the 
nasopharyngeal mucosa (Lin et al., 1997). According to previous reports, normal 
nasopharyngeal tissues are frequently infiltrated by lymphocytes and a small fraction 
(1/104-6) of some infiltrated B lymphocytes contains EBV genome (Alan et al., 1999). 
The EBV DNA detected in our study could come from infiltrating EBV infected B 
lymphocytes. Since the EBV signals from normal nasopharyngeal tissues were so 
much lower than those obtained from NPC tissues, the EBV signals obtained from 
NPC tissues were therefore largely tumour-specific.   
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Fig. 7 DNA profiling results of one NPC biopsy.  
PCRs were performed using primers specific for 48 EBV genes listed in Table 4 (lanes marked 1 
to 48), the DNA extracted from a NPC biopsy as the template. The products were 
electrophoresced on 1% agarose gel. Lanes marked M contain 100bp DNA markers with sizes 
indicated on the left. The predicted sizes of PCR products from reactions 1-48 were listed in 
Table 4.  
The genes that could not be efficiently amplified were pointed out on the top of lanes. For the 
reactions which produced nonspecific products, the specific products were pointed out by white 
arrows.   
 
 
GAPDH    EBNA-LP     BHLF1                      EBNA 3C 
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Fig. 8 DNA profiling results of one non-NPC tissue biopsy.  
PCRs were performed using primers specific for 48 EBV genes listed in Table 4 (lanes marked 1 
to 48), the DNA extracted from a non-NPC biopsy as the template. The products were 
electrophoresced on 1% agarose gel. Lanes marked M contain 100bp DNA markers with sizes 
indicated on the left. The predicted sizes of PCR products from reactions 1-48 were listed in 
Table 4.  
The genes that could not be efficiently amplified were pointed out on the top of lanes. For the 
reactions which produced nonspecific products, the specific products were pointed out by white 
arrows. 
 
3.2.3 EBV RNA profiling of tissue samples 
We used our profiling system to check RNA expression of EBV genes in 14 tissue 
GAPDH       BNRF1                                            EBNA1   
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samples, including 10 NPC and 4 non-NPC tissues. In order to prevent the false positive 
results caused by DNA contamination, we used DNase I to treat the isolated RNA 
before subjecting the RNA to reverse transcription to synthesize cDNA. We confirmed 
the absence of DNA contamination with DNase I treated RNA preparation by 
performing a “no-RT” PCR whereby the RNA preparation itself was used as the 
template. An RNA preparation free of DNA contamination would not produce a PCR 
product.  
     Initially, for each RNA preparation, we perform the “no-RT” PCR only on the 
positive control gene GAPDH. Later on, we realized that even when the “no-RT” PCR 
for GAPDH did not produce a product, the “no-RT” PCRs for some EBV genes could 
still produce products (data not shown). This could be due to the possibility that the 
copy number of EBV genome is higher than that of human genome in a given cell or 
tissue sample. Indeed, a typical EBV latency infected cell contains ten or more copies of 
EBV genome. Another possible reason for getting “no-RT” PCR products for some 
EBV genes but not for GAPDH could be that the amplification efficiencies for these 
EBV genes were somehow higher than that for GAPDH. Given this observation, we did 
a “no-RT” PCR control to accompany the RT-PCR for each EBV gene studied in the 
RNA profiling. The results of RNA profiling for a typical NPC and non-NPC biopsies 
are shown in Fig. 9 and 10 respectively. For these two tissue samples no product 
appeared in “no-RT” negative control PCRs lanes 1’-48’. It showed that the PCR 
products obtained in RT-PCR were indeed amplified form cDNAs.                
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After profiling all tissue samples, the profiling results for 10 NPC biopsies and 4 
non-NPC biopsies were summarized in Table 5. 
 













EBNA1      9 0 BHLF1      9      0 
EBNA2 0 0 BBLF1      7      0 
EBNA3 0 0 BALF5      7      0 
EBNA-LP      2     0 BARF1      7      0 
LMP1      4     0 RJLF3      6      0 
LMP2A      9     0 RJLF2      6      0 
LMP2B      5     0 BALF2      4      0 
BART2      7     0 BALF1      4      0 
   BMRF2      3      1 
   BMRF1      2      1 
   BRLF1      2      0 
   SM      2      0 
   BILF1      7      2 
   BNRF1 2      2 
   BNLF1      1      0 
   BRRF1      1      0 
   BDLF3      1      0 
   BXLF2      0      1 
* Except EBNA2 and EBNA3, EBV genes that never gave positive results in RT-PCR 
are omitted.  
 
As shown in this table, among latent genes, only EBNA1 and LMP2A were 
consistently expressed in almost all NPC biopsies; BARTs were expressed in the 
majority (70%) of NPC samples; LMP1 and LMP2B were expressed in about half of 
the cases. Transcript of EBNA-LP was detected only in 2 samples. In these two samples, 
the EBNA-LP transcripts detected were unspliced. Therefore they were not the 
messages for EBNA-LP protein production. The transcripts of EBNA3s and EBNA2 
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were absent. Based on our result, latent genes EBNA1, LMP2s, LMP1 and BARTs were 
expressed in most NPC biopsies, and this EBV gene expression pattern belongs to 
latency type I/II. This is consistent with previous studies (Brooks et al., 1992; Sadler et 
al., 1995).  
In addition to some latent genes, some lytic genes were found to be expressed in 
NPC biopsies. Among these lytic genes, the most consistently expressed gene was 
BHLF1. The transcripts of BHLF1 were detected in 90% NPC biopsies. In contrast no 
BHLF1 expression was detected from non-NPC samples. Although the RNA expression 
levels of BHLF1 were variable in different NPC samples, they were generally high 
compared with other EBV genes, especially in 2 samples.  
In addition to BHLF1, a few other lytic genes were also found to be expressed in 
NPC tissues. Transcripts of BBLF1, BALF5, BARF1, RJLF3 and RJLF2 were detected 
in more than half of NPC samples but not in non-NPC samples. Transcripts of BILF1 
were found in 70% NPC samples, but they were also detected in 2 of 4 non-NPC 
samples. Transcripts of BALF2 and BALF1 were only found in 4 NPC samples. 
Transcripts of BMRF2, BMRF1, BRLF1, SM, BNRF1, BNLF1, BRRF1 and BDLF1 
were detected in 1-3 samples of 10 NPC biopsies, and among these 8 genes, BMRF2, 
BMRF1 and BNRF1 were also detected in non-NPC samples. Totally, we found EBV 
RNAs derived from the genomic regions of 17 lytic genes. Compared with the RNA 
profiling results of NPC cell line C666-1, we found that the number of genes expressed 
in NPC tissue samples is much less than in C666-1 cell line.  
The most outstanding result of our RNA profiling of tissue samples is the 
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presence of BHLF1 RNA specifically in NPC tissues and the transcription levels were 
relatively high. Since the BHLF1 RNA is polyadenylated, it is likely that it is translated 
to produce BHLF1 protein. It is unlikely that the transcript of BHLF1 was from the 
infiltrating B lymphocytes in the NPC biopsies, because it was not found in non-NPC 
nasopharyngeal tissues which also contain a lot of B lymphocytes. It is more likely that 
this gene is expressed in NPC malignant epithelial cells. To confirm this possibility, we 
need to do RNA in situ hybridization for BHLF1 on NPC tissues.   
BBLF1 sequence-containing RNA was also found in most NPC biopsies, but we 
are not sure if BBLF1 is expressed at the protein level. BBLF1 is located in a nested 
transcription unit that includes two other genes BGLF5 and BGLF4. Since BBLF1 is 
downstream of BGLF5 and BGLF4, the RNAs for the translation of BGLF5 or BGLF4 
also contain BBLF1 sequence (as shown in Fig. 11). With only the RT-PCR data, we 
cannot tell if the BBLF1 sequence-containing RNA is for BBLF1 translation.         
Fig. 11 BBLF1, BGLF1 and BGLF4 transcription map.  
The transcript of individual gene (from the transcription initiation site to 
polyadenylation signal) was indicated with         . 
 
EBV lytic gene BGLF5 has been reported to be expressed in NPC biopsies 
(Sbih-Lammali et al., 1996). However, in our profiling study, we did not detect the 
BBLF1 BGLF5 BGLF4 
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BGLF5 sequence-containing RNA. Since the BGLF5 sequence is relatively far (2kb) 
upstream of the polyadenylation signal, the cDNA synthesis primed with oligo-dT and 
performed by a reverse transcriptase with low-processing activity as in our study may 
reach this sequence very inefficiently. That may explain why we were unable to detect 
BGLF5 RNA in our profiling study. To study if BGLF5 might be expressed, we 
performed RT-PCR using BGLF5 gene specific reverse primer to synthesize the cDNA. 
With this method, we detected BGLF5 sequence-containing RNA from a NPC biopsy 
(data not shown). However, this detected RNA could be the one for BGLF5 or BGLF4 
translation. We did not study this case any further. 
Transcript of BARF1 was found to be expressed in about 70% NPC biopsies and 
not in non-NPC biopsies. It has been reported that this gene are expressed in about 80% 
NPC tumour biopsies (Tanner et al., 1997). Our results are consistent with these data.        
     In NPC biopsies, we frequently detected RNAs derived from the EBV genomic 
region where BALF5, RJLF3, RJLF2, BALF2, BALF1 and BILF1 genes reside. This 
EBV genomic region is actually transcribed in both directions (as shown in Fig. 12). 
While the leftward transcription gives rise to the RNAs of the above mentioned genes, 
and the rightward transcription gives rise to a huge (22kb) primary transcript called 
BART which is then differentially spliced into many small RNAs (Smith et al., 2001).  
Since our RNA profiling reactions do not distinguish the orientation of the RNA in a 
genomic region, we could not tell whether the detected transcripts were those of the 
leftward-oriented genes or BARTs. This issue was resolved by orientation-specific 
RT-PCR (see section 3.2.4).  
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Fig. 12 Transcription map of genes within or near Bam HI A region  
The transcript of individual gene (from the transcription initiation site to 
polyadenylation signal) was indicated with         . 
        
We also found some other lytic genes occasionally expressed in NPC biopsies, 
such as BRLF1, BMRF2 and BMRF1. According to previous paper, BRLF1 RNA 
should be expressed in most NPC biopsies (Feng et al., 2000), but in our study the 
results were different. This might be due to the different method we used for detecting 
RNAs. In the previous study, nested PCR and subsequent probe hybridization were 
employed to detect the EBV RNAs. This method is more sensitive than our method. 
This might explain the difference in the results. 
The EBV RNA profile of C15, a nasopharyngeal carcinoma tumour propagated in 
nude mice (Hitt et al., 1989), is similar to that of the NPC tissues which we obtained. 
RNAs from the EBV Bam HI-A region and a low level of RNA from the BamHI-H 
region were detected in C15. A further study on C15 indicated that BHLF1 might be 




BILF1 BALF5 RJLF2 RJLF3 BALF4 BALF3 BALF1 
Bam HI A rightward transcripts (BARTs) 
BALF2 
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3.2.4 Orientation-Specific RT-PCR   
In order to tell the orientation of the transcripts of BILF1, RJLF3, RJLF2, BALF5, 
BALF2, BALF1 and BARTs, we added only EBV gene specific forward or reverse 
primers to prime the reverse transcription. If the transcripts were leftward, the specific 
PCR product should be appeared only when forward primers were used to prime the 
RTs (refer to Fig. 13, lanes 1’-10’). In opposite, if the transcripts were rightward, the 
specific PCR products should be appeared only when we used reverse primers to prime 
the RTs (refer to Fig. 13, lanes 1-10). The testing results were shown in Fig. 13.  
In this test, we got a number of non-specific products in many reactions, for 
example, the reaction for BALF5 using either the reverse or forward primer to prime the 
RT (Fig. 13, lanes 3 and 3’). We have not optimized this orientation-specific RT-PCR 
protocol. However, the current results were clear enough for us to draw the conclusions 
as described below.   
The specific PCR products at the BALF2, BALF5, BILF1, RJLF1, RJLF2, RJLF3 
and BALF1 regions appeared when we used reverse primers to prime the RTs (as shown 
in Fig. 13, lanes 1, 3, 4, 5, 6, 7 and 10 respectively), and not appeared when forward 
primers were used. It showed that all these RNAs were rightward transcripts, and 
therefore the transcripts of these genes were indeed the BARTs which have been 
reported to be expressed in NPC tissues (Sadler et al., 1995). The transcripts of BALF2, 
BALF5, BILF1, RJLF2, RJLF3 and BALF1 which we detected in NPC biopsies were 
actually not expressed in the NPC tissues.  
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Fig. 13 Orientation test of transcripts of some EBV genes.  
One-Step PCRs were performed using the primers specific for EBV genes shown on the top of 
each panel, and reverse primers (lanes marked with 1-10) or forward primers were used to prime 
(lanes marked with 1’-10’) the RTs. The products were electrophoresced on 1% agarose gel. 
Lanes marked M contain 100bp DNA markers with sizes indicated on the right. For each 
reaction the specific product was pointed by white arrow. 
 
     We also used the same method to check the orientation of the RNAs detected in 
the BHLF1 and BARF1 regions. The specific PCR product at the BHLF1 region 
presented when forward primer were used to prime the RTs (as shown in Fig. 13, lane 
8’). On the contrary, the specific PCR product at BARF1 region presented when reverse 
primer were used (as shown in Fig. 13, lane 9). It showed that the directions of 
transcripts of BHLF1 and BARF1 were correct, and therefore these two genes were 
  BALF2   BART  BALF5  BILF1   RJLF1  RJLF2  RJLF3     
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really expressed in NPC biopsies. In addition, there might be a small amount of 
rightward RNA in the BHLF1 region because the specific product also appeared when 
reverse primer was used to prime the RTs (as shown in Fig. 13, lane 8).  
For BART, we detected several PCR products in the range of 100bp-400bp when 
we used reverse primer to prime the RTs (as shown in Fig. 13, lane 2). It showed that 
BART was differentially spliced in NPC biopsies as previously described (Smith et al., 
2001). 
In conclusion, though we found RNAs from several lytic gene regions in NPC 
biopsies, BHLF1, BARF1 and BGLF5 may be the only lytic genes that are really 
expressed. BGLF5 (Sbih et al., 1996) and BARF1 (Tanner et al., 1997) had been 
reported to be expressed in NPC biopsies before. Expression of BHLF1 in NPC has 
never been reported.  
Comparing the RNAs profiling results of NPC biopsies with those of the NPC 
cell line C666-1, we found that most of the EBV RNAs we detected in NPC biopsies 
were also appeared in this cell line. The EBV latent gene expression patterns of the 
NPC biopsies studied were similar to that of C666-1 cell line. In term of lytic genes, 
transcripts from the genetic regions of BHLF1, BBLF1 and BARF1 which were found 
to be expressed in more than half of NPC biopsies were also detected in C666-1 cells. 
Therefore, C666-1 cell line should be a good model for studying EBV gene expression 
regulation in NPC tumour cells.            
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3. 3 PART 3: CONCLUSION 
NPC is a malignancy of the stratified squamous epithelium of nasopharynx. This 
carcinoma is rare in most countries, but it has a high incidence in South-East Asia. As 
we had discussed before, this carcinoma is consistently associated with EBV infection, 
and EBV have been considered as an important factor in the oncogenesis of NPC. EBV 
has been proven to exist in the nasopharyngeal epithelial cells of NPC patients, but not 
in untransformed squamous epithelia from the nasopharyngeal mucosa (zur Hausen et 
al., 1970; Lin et al., 1997). It is generally accepted that EBV infection in NPC tumour 
cells is predominantly latent, and EBV latent gene expression is consistently detected in 
tumour cells, including EBNA1, LMP1, LMP2, BARTs and EBERs. Previous studies 
mainly focus on these EBV latent genes and their function in oncogenesis of NPC. In 
contrast, less research has been done to study the EBV lytic genes. However more and 
more data suggest that EBV lytic genes are expressed in NPC tumour cells, and maybe 
contribute to the development of NPC (Wei et al., 1997; Sbih-Lammali et al., 1996; 
Feng et al., 2000). Based on this background, our study was designed to find what EBV 
genes are expressed in NPC biopsies. In fact, this is the first comprehensive study of 
EBV gene expression in primary NPC tissues. The results present in this study add 
some valuable information to current knowledge of EBV lytic genes expression pattern 
in NPC tumour cells, and provide some clues to understand the involvement of EBV in 
the development of NPC.    
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3.3.1 Successfully construct a profiling system to check the transcripts of EBV 
genes  
By using RT-PCR technique, we constructed a reliable profiling system to detect 
the transcripts of EBV genes in NPC biopsies. We have shown that this system 
successfully detected the transcripts of EBV genes in different EBV cell lines and NPC 
biopsies. This profiling system should be a useful tool for revealing the EBV gene 
expression in tissues of other EBV associated diseases.  
This system also has some defects. First, our profiling method is not as sensitive 
as nested PCR plus probe hybridization which has been used in previous studies. 
Therefore some transcripts which have been reported to be expressed in EBV cell lines 
or NPC biopsies were not detected in our study. It is not possible for us to use such a 
highly sensitive but tedious method to detect RNAs of all EBV genes. Moreover, 
extreme low levels of RNA expression which can only be detected by this highly 
sensitive method may not be physiologically significant. Based on this consideration, 
we prefer to use our method in this study. Second, our profiling system only can detect 
EBV RNAs, and we do not know whether the RNAs translate to proteins. Third, this 
system only looks at RNAs in batch, but not in individual cells. Though this system has 
some defects, it is good to be used in a preliminary study of EBV gene expression to 
provide clues for further studies.       
    
3.3.2 Lytic gene expression in NPC biopsies  
     Although it is generally accepted that EBV infection in NPC is predominantly 
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latent, our profiling results of NPC tissue biopsies and NPC cell line (C666-1), as well 
as data from other groups (Feng et al., 2000; Tanner et al., 1997; Wei et al., 1997; Sbih 
et al., 1996), show that a small number of EBV lytic genes are expressed in NPC in 
addition to latent genes. It appears that the lack of expression of some genes essential 
for the lytic replication disallows virus production and cell killing, and locks the cells in 
an abortive lytic stage. Some of the expressed lytic genes may contribute to the 
proliferation potential of the tumour cells. For instance, among the lytic genes 
frequently expressed in NPC biopsies, BARF1 was shown to have the transforming 
ability (Wei et al., 1989; Deaussin et al., 2000).  
 
3.3.3 BHLF1 expression in NPC biopsies 
     The transcript of BHLF1 was first found in this study to be expressed in NPC 
biopsies. BHLF1 is an unusual gene. It consists almost entirely of tandem repeats of a 
125bp G-C-rich sequence. Each sequence repeat contains a recognition site for the 
rare-cutting restriction enzyme Not I and therefore is called Not I-repeats (Pfitzner et al., 
1987). Accordingly, the BHLF1-encoded protein consists almost entirely of tandem 
repeats of 125 amino acids. It is a very basic protein consisting mainly of proline (22%), 
alanine (16%), glycine (16%) and arginine (13%). It has been detected in EBV infected 
lymphocyte cell lines, exists in nuclear patches colocalizing with nucleoli, and has the 
ability to strongly bind single-stranded DNA in vitro (Lieberman et al., 1989; Nuebling 
et al., 1989). In vitro studies on latently infected B-lymphocyte cell lines have shown 
that BHLF1 is an early lytic gene and its transcripts are the most abundant EBV-specific 
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transcripts in the early phase of lytic cycle (Laux et al., 1985). BHLF1-encoded protein 
belongs to subgroup EA-D of EBV-encoded antigens. Although the BHLF1 is the most 
actively transcribed gene during lytic EBV infection, the precise function of the BHLF1 
gene product remains unknown. With the fact that the promoter of BHLF1 overlaps 
with the essential domain of the viral origin of lytic replication (Hammerschmidt et al., 
1988), BHLF1 may play a role in the regulation of lytic replication. A study on human 
tonsillar lymphocytes has suggested that BHLF1 protein has a function in the regulation 
of viral gene transcription (Yamamoto et al., 1989).           
Previous study about EBV gene expression in NPC biopsies did not detect the 
transcripts of BHLF1 (Xue et al., 2000). This may caused by the different primers we 
used for PCR. We tried to repeat their experiments, and found that their primers for 
BHLF1 could not efficiently amplify EBV specific sequence even from EBV DNA. 
Therefore, after reverse transcription, they could not detect the transcript of BHLF1.         
 
3.3.4 Further studies on BHLF1 
     In this preliminary study, we showed that transcripts of BHLF1 were consistently 
expressed in NPC biopsies. Further studies need to do to confirm our results and to 
evaluate the possible significance of BHLF1 in the development of NPC. First, we need 
to profile more tissue samples to confirm that the transcripts of BHLF1 are expressed in 
most NPC biopsies and not expressed in non-NPC tissues samples, because the number 
of biopsies which we used in this study is not enough, especially the number of 
non-NPC samples. Second, we need to test the origin of BHLF1 transcripts. RNA in situ 
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hybridization should be performed using BHLF1 gene-specific probes to test whether 
the transcripts come from the NPC tumour cells or just from infiltrating B-lymphocytes. 
Third, in order to test if the BHLF1 encoded protein is present in NPC cancer cells, we 
may clone, express and purify the BHLF1 encoded protein, and use the purified protein 
to immunize animals to get BHLF1-specific antibody, and then use the antibody to 
perform immunohistochemical studies to test the if BHLF1 encoded protein present in 
NPC tumour cells. Fourth, in order to test if BHLF1 has an effect on cell proliferation, 
we can express the BHLF1 encoded protein in primary monkey epithelial cells to 
observe the effect of this protein on the growth of epithelial cells or we can silence 
BHLF1 gene expression in NPC cell line C666-1 using siRNA to observe the change of 
the cells. In addition, we can use the purified BHLF1 encoded protein to profile 
antibody response in NPC patients’ blood. If the antibodies against BHLF1 encoded 
protein specifically appear in most NPC patients’ blood and do not appear in normal 
people’s blood, it is possible for this protein to be a new candidate of NPC diagnostic 
markers.  
 
In summary, in this study we first successfully constructed a profiling system 
which can detect the RNA expression of EBV genes in EBV-infected cells. Then we 
used this system to profile EBV transcripts in NPC biopsies. Profiling results showed 
that some lytic genes were transcribed in NPC biopsies. Among these lytic genes, 
BHLF1 have not been found to be expressed in NPC before. Additional studies are 
required to determine the relevance of BHLF1 expression to the development of NPC. 
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Appendix 1: Sequences of oligonucleotide primers 




1 GAPDH 5’primer  5’ACGCCTGCTTCACCACCTTCT
TG3’ 
  3’primer  5’GGAGCCAAAAGGGTCATCAT
CTCTG3’ 
2 BNRF1 5’primer 4671-4692 5’TGCTGCTGGGAACCTGGTCAT
C3’ 
  3’primer 5382-5359 5’TTAGTAAATTGCAGGCCCAGG
CAC3’ 
3 BCRF1 5’primer 9712-9734 5’TGCTGCTTTACCTGGCACCTG
AG3’ 
  3’primer 10221-10198 5’TGCACCCATCTCCTGCTTCCA
GGG3’ 
4 BCRF2 5’primer 46753-46774 5’CAGGCCCCAGAGTCCAGAGG
TC3’ 
  3’primer 47303-47282 5’GGAGAAAAGCTGGCGCCCTT
GC3’ 




  3’primer 47947-47925 5’ATTGGCGCTGGGTGGTTACTG
TG3’ 
6 EBNA2 3’ 5’primer 48815-48837 5’TGCCTGGACACAAGAGCCAT
CAC3’ 
  3’primer 49520-49496 5’CTGGCCTTGAGTCTTAGAGGG
TTGC3’ 
7 BHLF1 5’primer 50325-50352 5’GGCTGCTTTTAGCCTAATTGT
GTATTGC3’ 
  3’primer 50561-50540 5’CTGCCCATGGAATGCTCAGAC
C3’ 
8 BHRF1(SJ) 5’primer 53835-53858 5’GGTTTCGTCTGTGTGTTGAAG
GGC3’ 
  3’primer 54830-54808 5’GTAGACCAGCCGCCCTGTTGA
TG3’ 
9 EBNA2(SJ) 5’primer 47761-47780 5’CCACTACGGCCACGTCCCCG3
’ 
  3’primer 48619-48597 5’TGTTCCTGGTAGGGATTCGAG
GG3’ 
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Sequences of oligonucleotide primers (continued) 




10  BFLF2 5’primer 56133-56156 5’CAGAAGGCGTCCCCTACTAGG
TCC3’ 
  3’primer 56738-56715 5’ATCAATATGTTCCCGGCACAC
CAG3’ 
11  BFLF1 5’primer 57087-57113 5’ACAAGCGTAATTAACGAGTCA
CAGACC3’ 
  3’primer 57753-57730 5’TGCCTACCAGAAACCGAGTTC
AGC3’ 
12  BFRF1 5’primer 58900-58923 5’CCGGAAGAGAGGCTCCTAGA
CGAG3’ 
  3’primer 59595-59573 5’GTTATCCAAGTCCCAACCACC
GC3’ 
13 BFRF2  5’primer 60606-60629 5’GCTGATCATGCCTCGGCTCTA
TTG3’ 
  3’primer 61271-61250 5’GATGATGGCATCCAAGAGGCG
G3’ 
14 BFRF3 5’primer 61588-61613 5’CAAGAGCTGAACCAGAATAA
TCTCCC3’ 
  3’primer 62045-62021 5’CGTGCCCTCTACTGTTTCTTAC
GTG3’ 
15 BPLF1 5’primer 62154-62178 5’TGGCTCACGAAGCGAGACAG
TACTC3’ 
  3’primer 62547-62524 5’CCCAAACATACACCGTGCGA
AAAG3’ 
16 BOLF1 5’primer 72264-72288 5’ATACAGGATGTCGTCCATGCT
GAGG3’ 
  3’primer 72969-72947 5’CACCCTGAGATACAGCACGA
CGG3’ 
17 BORF1 5’primer 75473-75494 5’GCTTCAGCTGGTCTGGGTGGC
G3’ 
  3’primer 76153-76130 5’CATAGCGGTGCATGATGGATG
GTG3’ 
18 BORF2 5’primer 78076-78098 5’GGCACGATTGGGCAGGAACA
GAC3’ 
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Sequences of oligonucleotide primers (Continued) 




19 BaRF1 5’primer 79121-79145 5’CTTCGAGAGCCACGACATTGA
TCAC3’ 
  3’primer 79788-79763 5’GCATGGTGTAATCGGAACTCT
CTTGC3’ 
20 BMRF1 5’primer 80067-80090 5’GGGCTAATCAGCTTCGAGGTC
TCC3’ 
  3’primer 80774-80750 5’AACACTAAGATCCAACGGCA
GGTCC3’ 
21 BMRF2 5’primer 81477-81501 5’CATCGAGATTGTTTACATCTG
CCCG3’ 
  3’primer 82023-82000 5’GATAAACAGCACGGTCTTGCC
CAG3’ 
22 BMLF1 5’primer 82790-82811 5’CCGGAGAGAGAATGGCCCTG
AC3’ 






  3’primer 84269-84245 5’TCTCCCGAACTAGCAGCATTT
CCTC3’ 
24 BSLF1 5’primer 84423-84447 5’AAGCACTGACTCATGAAGGT
GACCG3’ 
  3’primer 84966-84943 5’CGCATACCTACAAGGTGGACA
GGG3’ 
25 BSRF1 5’primer 86924-86949 5’ATGGCCTTCTATCTCCCAGAC
TGGTC3’ 
  3’primer 87580-87558 5’CTACGTTAACGCGAGCTCCGT
GG3’ 
26 BLLF3 5’primer 87625-87650 5’GGATATGAAGGTGTCATTGAC
CCGAG3’ 
  3’primer 88353-88321 5’GGACCTAGGCCTCTATGCCCG
CC3’ 
27 BLRF1 5’primer 88555-88579 5’GGTCCTAAGAAAGCCGTTTGC
AAAG3’ 
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Sequences of oligonucleotide primers (Continued) 




28 BLRF2 5’primer 88927-88951 5’GTCAGCTCCACGCAAAGTCA
GATTG3’ 
  3’primer 89337-89314 5’TTTGATTCTCGTGGTCGTGTT
CCC3’ 
29 BLLF2 5’primer 89435-89459 5’CATAGGTCTCGGCGTCATCATA
TGG3’ 
  3’primer 89954-89929 5’GGAAACAGTTCCACATCCAC
AAAACC3’ 
30 BLLF1(SJ) 5’primer 89701-89725 5’GTGGTCGCATTGTATCTCGGT
CTTG3’ 
  3’primer 90683-90661 5’AGTCCATCTCCATGGGACAAC
GG3’ 
31 EBNA 3A 5’primer 93566-93588 5’CACTTATGGCACACCTAGGCC
GC3’ 
  3’primer 94186-94164 5’GGCTGCACCTCAACACTAGCC
TG3’ 




  3’primer 96254-96232 5’GTGCCCAGCCCAATCCATATA
GC3’ 
33 EBNA 3B 5’primer 96834-96855 5’ACTGAGTGTCCAGGCTCGGCT
G3’ 
  3’primer 97227-97206 5’CACCGGCCATGGAGTTTGTGC
G3’ 




  3’primer 99263-99240 5’GATGTGGTGCAGAGAGCCAC
ACAG3’ 
35 EBNA3C 3’ 5’primer 100675-100698 5’AGGCTCCATACCAGGGATACC
AGG3’ 
  3’primer 101323-101301 5’TCAGCAGTAGCTTGGGAACA
CCG3’ 
36 BZLF2 5’primer 101486-101512 5’GGAATGAACACTCATGGTGTG
AGACTG3’ 
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Sequences of oligonucleotide primers (Contiuned) 




37  BZLF1(SJ) 5’primer 102167-102190 5’TAGTAAACGAGGCGTGAAGC
AGGC3’ 
  3’primer 103031-103009 5’CTCCTTTGCCTTGTGTGCTGT
GG3’ 
38 BRLF1 5’primer 103340-103364 5’GAGGAGGAGGCAGTTTTCAG
AAGTG3’ 






  3’primer 105123-105100 5’CAGCTGGGCTCTCTGGTCTCT
GAC3’ 
40 BRRF1 5’primer 105385-105407 5’CAAGCTGCTGGAAGACACCA
TCG3’ 
  3’primer 106035-106013 5’GGCAGGGTAATGGCATCCGTG
AC3’ 
41 BRRF2 5’primer 107178-107204 5’CGCGTTGTTGTTATTGATTCCT
CTTTG3’ 
  3’primer 107909-107885 5’GACGCTCAGTGAATACAGGG
AGTGC3’ 
42 EBNA1 5’primer 109205-109227 5’AAGAAGGTGGCCCAGATGGT
GAG3’ 
  3’primer 109870-109849 5’CCTGCCCTTCCTCACCCTCAT
C3’ 
43 BKRF2 5’primer 109959-109982 5’TGCGTGCTGTTGGTGTATTTC
TGG3’ 
  3’primer 110292-110269 5’TCCAGGGTGGTTAACAACTCA
CGG3’ 
44 BKRF3 5’primer 110494-110517 5’CTTGCTGCCGTTATTGCCTGT
GTC3’ 
  3’primer 111027-111005 5’ACTCTTTCGGGTGCTGTTCTG
GG3’ 
45   BKRF4 5’primer 111187-111210 5’CTTGTCGGACGAGGAGGAAG
AGAC3’ 
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Sequences of oligonucleotide primers (Continued)  




46 BBLF4 5’primer 111838-111862 5’CCAGTAGTGCGCGTGAGTTCT
TTAG3’ 
  3’primer 112548-112525 5’CCGCTGTCTTCTATGCCCGAG
TAC3’ 
47 BBRF1 5’primer 115095-115117 5’CTGGCCCATCTGGAGCAGAA
CTC3’ 
  3’primer 105677-105653 5’CGCTTTCCCAAAGTTCAGTCA
GATC3’ 
48 BBRF2 5’primer 116072-116096 5’CCAACGTCCCTGAGTTCTACA
ATGC3’ 
  3’primer 116720-116697 5’GTCTGGCACTGGAAATGCTTG
GTC3’ 
49 BBLF3 5’primer 116826-116850 5’GATTTCCATAGGAATGGTGTA
GCCG3’ 
  3’primer 117305-117283 5’CGCAGACACATTCGGGTGAA
GGC3’ 
50 BBLF2 5’primer 117523-117544 5’GTGGCTCCTCTGAAGGATGGG
C3’ 
  3’primer 118044-118021 5’TGCTACTGGACCTGAACCTGG
GAG3’ 
51 BBLF2(SJ) 5’primer 116826-116850 5’GATTTCCATAGGAATGGTGTA
GCCG3’ 
  3’primer 117577-117555 5’GAGTTCATCCTGGGCTTTGTG
GC3’ 
52 BBRF3 5’primer 119610-119635 5’TTTGCACTTTCTGGCCTCAGT
TCTAC3’ 
  3’primer 120270-120246 5’CCTGGTTGACCTGGAGGAAG
ATGAG3’ 
53  BBLF1 5’primer 120790-120815 5’TCAGAGTCCTCATCATATTCG
AGCCC3’ 
  3’primer 120998-120975 5’AGACAATACTTTTGACACCGC
GCC3’ 
54 BGLF5 5’primer 121351-121373 5’CGCTTGGGTCCGTCATTACGT
AG3’ 
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Sequences of oligonucleotide primers (Continued) 




55 BGLF4 5’primer 122467-122491 5’TGCAAGAATTGACTCATATGC
TCCG3’ 
  3’primer 123129-123105 5’CTGGCATGATGGTAGTATTGA
GCCC3’ 
56  BGLF3 5’primer 124220-124242 5’CAGGCGGCTAACGTCAAAGG
GAG3’ 






  3’primer 129751-129726 5’TGATGCGGATGTGTTGTTGGT
ATAGG3’ 
58 BGLF2 5’primer 125904-125928 5’TGTAGAGCATAGCCCGGCTGT
AAAG3’ 
  3’primer 126531-126509 5’GAGGCGGTGCCTGTGGAGATT
AG3’ 
59 BGLF1 5’primer 127242-127267 5’CGGGAGTAGGAGGTGGGAAT
AACAAC3’ 
  3’primer 127957-127936 5’CAGGAGTCTGCTGCGGCTATG
C3’ 
60 BDLF4 5’primer 128486-128511 5’TAGAGACTGAGGACCACATC
CACCAC3’ 
  3’primer 128932-128908 5’GGAGTTCCATCTCCCGTTACC
TGAG3’ 
61 BDRF1 5’primer 129690-129715 5’GCCTAGCCTCCTCCCTCTACG
TGTAC3’ 
  3’primer 130324-130300 5’CTGTGTTGTTGCGAGAAAATG
AGCC3’ 
62 BDLF3 5’primer 130402-130424 5’GCATTCGTGAGCAGGGCTTCG
TC3’ 
  3’primer 131053-131031 5’GAGACAAGGCAGGCGCTGTT
ATG3’ 
63 BDLF2 5’primer 131182-131204 5’GTGAGCCGGTCAACACGACA
TTG3’ 
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Sequences of oligonucleotide primers (Continued) 




64 BDLF1 5’primer 132527-132549 5’TCATCCGCCACTGACAGGTCA
TC3’ 
  3’primer 133178-133155 5’TGGGCTTGGGTCAGGTGTACT
CTC3’ 
65 BcLF1 5’primer 133806-133830 5’CGGCAACCTCCTGATTGTAGT
TTTC3’ 
  3’primer 134433-134409 5’CTCGTTTCAATCAGTGGAATG
ACCG3’ 
66 BcRF1 5’primer 138988-139010 5’CGGCCGTGTCAAACTGGAAC
TCG3’ 
  3’primer 139716-139694 5’ACACTTGAGCATCACGGCAGT
GG3’ 
67 BTRF1 5’primer 139948-139974 5’CCCTATATCCTAGAGGGACAG
CTGACG3’ 
  3’primer 140590-140567 5’CCTTGGTTTCAGCCTCACTGA
TGG3’ 
68 BXLF2 5’primer 140937-140963 5’CTTGTGAACCAGAAAGATACC
CAGAGC3’ 
  3’primer 141611-141589 5’TCACCGTGCTACCTCAGCCTA
CG3’ 
69 BXLF1 5’primer 143063-143087 5’TCAGAGATCACCTTGCTCAGA
CCAG3’ 
  3’primer 143735-143714 5’AGTCTGGTGCCAGGTCAGTC
GC3’ 
70 BXRF1 5’primer 144901-144925 5’CCTGGCAAAATTTCACAGTCT
TCCC3’ 
  3’primer 145512-145490 5’GCAGTGAGTTGCGAAGGCTT
GGG3’ 
71 BVRF1 5’primer 146459-146481 5’CCGGATCGCCAACCAGATCTT
TG3’ 
  3’primer 147166-147143 5’CTTTTTGCCAATGACCCACTC
CAG3’ 
72 BVRF2 5’primer 147935-147957 5’GGCACCGTCTGTATACGTCTG
CG3’ 
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73 BdRF1 5’primer 149012-149033 5’GGCGATGGACGCTCACACCTA
C3’ 
  3’primer 149697-149676 5’GGTGGGCTGACACAGACTTG
GC3’ 
74 BILF2 5’primer 149821-149842 5’CAGCCACCCCAGACAGGAGA
TG3’ 
  3’primer 150385-150364 5’GGTCTCTCGGATCGAGTTGGG
C3’ 
75 BILF1 5 ’ 5’primer 150602-150626 5’TATTCTGCAACAACAGCCATA
CCCG3’ 
  3’primer 151204-151181 5’AAGATGCACTTGCATATTCCG
GGC3’ 
76 RJLF3 5’primer RJ*851-874 5’TCAGAATAACAGGGGAAGCA
AGGC3’ 
  3’primer RJ*1028-1007 5’AGGGACAGGGGGAGACTTTC
GG3’ 
77 RJLF2 5’primer RJ*9334-9361 5’GGCTACGATATTCCCGTTAAAT
GTCTTG3’ 
  3’primer RJ*10009-9988 5’CGAGTGCCTGCCTTACCTGCT
G3’ 
78 RJLF1 5’primer RJ*10862-10884 5’ACGCCGCCTCCTGGAATGTAA
AC3’ 
  3’primer RJ*11635-11612 5’TCATTTGTGTAGGTGCGGCTA
TCC3’ 
79 BILF1 5’primer 152262-152285 5’TAATGAGCAACAGGGCCAAA
CAGG3’ 
  3’primer 152868-152847 5’GAACTGCTGCTCTGGGTGCTG
G3’ 
80 BALF5 5’primer 153721-153743 5’AAATTCTGGAGGACGGAGAG
GGC3’ 
  3’primer 154375-154354 5’TCTCCCTGGAGGCCGAGAAG
AC3’ 
81 ECRF4 5’primer 155444-155466 5’CGGTGATGCGGACCTTGGTGT
TG3’ 
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82 BALF4 5’primer 156785-156807 5’GGCGGTCTCTGGATCGTGATA
GC3’ 
  3’primer 157410-157387 5’TTGCCTCCCTGGAGCTGTACT
CAC3’ 
83 BART1(SJ) 5’primer 156051-156073 5’GTTGGCCTCAAAGATCCGACA
CC3’ 
  3’primer 157360-157338 5’TTTGACCTGGAGGGCATCTTC
CG3’ 
84 BART2(SJ) 5’primer 159120-159142 5’CACTGGATGTCCGAGGAGAA
GCG3’ 
  3’primer 160921-160900 5’TGGATCTGCTGGGCCGCTTTC
G3’ 
85 BART3(SJ) 5’primer 159812-159836 5’AGCTCAGGGTCTGGGTAAAC
AGGTG3’ 
  3’primer 160921-160900 5’TGGATCTGCTGGGCCGCTTTC
G3’ 
86 BALF3 5’primer 160451-160472 5’ACAGGGCAGAGAGGCGGGAA
TG3’ 
  3’primer 161124-161103 5’GCTGCTCGCCCCTGGTAGAAA
G3’ 
87 BALF2 5’primer 161501-161524 5’CTCGGCCACGCTGATAAAGTT
GTC3’ 
  3’primer 162086-162065 5’CGCGGCCACAGACTGTCTTAG
C3’ 
88 BALF1 5’primer 164862-164886 5’GATTTCAGGAAGTCAGTCAG
GCTGG3’ 
  3’primer 165547-165525 5’ACACAGGAGGCCAACAGGAG
GAG3’ 
89 BARF1 5’primer 165514-165536 5’TCATCGCTCAGCTCCTCCTGT
TG3’ 
  3’primer 166121-166098 5’GTCATTTTTCCCAACGCAGGT
CAC3’ 
90 BNLF2 5’primer 166964-166989 5’CATCAATAATAAGGGCGCCAT
CTAGC3’ 
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91 LMP1 3’ 5’primer 167531-167554 5’AGGACAAGGAAAGAAGGCCA
GAGG3’ 
  3’primer 168222-168199 5’TCTGGTTCCGGTGGAGATGAT
GAC3’ 




  3’primer 169072-169049 5’ATTGTGCTGTTCATCTTCGGG
TGC3’ 




  3’primer 169379-169357 5’CCTCTTGGCGCTACTGTTTTG
GC3’ 
94 LMP2A 5’ 5’primer 166656-166680 5’ATCTGCTTCTGGCTCTTCTGG
GAAC3’ 
  3’primer 166911-166888 5’TCTGCCCGCTTCTTCGTATATG
TG3’ 
95 LMP2B 5’ 5’primer 169754-169777 5’GCAACAGGAAATGGAAAGGC
AGTG3’ 
  3’primer 169872-169851 5’GCCAACGACCTCCCAACGTT
GC3’ 




  3’primer 5801-5779 5’GTTCACGTCCAGCTTCTCCAT
GC3’ 
97 EBER1 5’primer 6647-6671 5’GAGGTTTTGCTAGGGAGGAG
ACGTG3’ 
  3’primer 6780-6757 5’CCAGCTGGTACTTGACCGAA
GACG3’ 
98 EBER2 5’primer 6959-6982 5’ACAGCCGTTGCCCTAGTGGTT
TCG3’ 
  3’primer 7117-7094 5’ACAAGCCGAATACCCTTCTCC
CAG3’ 
RJ*: indicate sequences from EBV Raji strain 
(SJ): indicate the PCR product across spliced region 
 
 
 
